[
    {
        "number": "1",
        "institutes": "Aegis Biodefense",
        "country": "USA",
        "type": "Commercial",
        "name": "Unnamed vaccine",
        "platform": "DNA",
        "licenced": "unknown  ",
        "pipeline": "unknown  ",
        "capacity": "unknown  ",
        "alliance": "unknown  ",
        "phase": "Phase I",
        "start_date": 1591700400,
        "reference": "NA (direct contact) https:\/\/aegis.bio\/",
        "phase1_country": "Japan",
        "phase1_start": 1593428400,
        "phase1_end": 1601118000,
        "phase1_trial": "NCT04463472; JapicCTI-205328",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$1,190,000.00",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 0,
        "phase0_start": 1591700400,
        "phase0_end": 1593428400,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591700400,
            1593428400,
            0,
            0,
            0
        ],
        "end_dates": [
            1593428400,
            1601118000,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "2",
        "institutes": "Entos Pharmaceuticals",
        "country": "Canada",
        "type": "Commercial",
        "name": "Fusogenix DNA vaccine",
        "platform": "DNA",
        "licenced": "None",
        "pipeline": "one vaccine not disclosed",
        "capacity": "none",
        "alliance": "University of Alberta, Govt of Canada funding $4.2 million",
        "phase": "Pre-clinical",
        "start_date": 1584619200,
        "reference": "https:\/\/www.pharmaceutical-business-review.com\/news\/entos-pharmaceuticals-fusogenix-covid-19\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$1,770,000.00",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 1,
        "phase0_start": 1584619200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584619200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "3",
        "institutes": "Genexine Consortium",
        "country": "Republic of Korea",
        "type": "Commercial",
        "name": "GX-19",
        "platform": "DNA",
        "licenced": "None",
        "pipeline": "HPV DNA vaccine Phase II",
        "capacity": "Genexine and Binex are preparing to scale up the consortium\u2019s manufacturing facility",
        "alliance": "Genexine, Binex, GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology and Pohang University of Science and Technology.",
        "phase": "Phase I\/II",
        "start_date": 1584360000,
        "reference": "http:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=7727",
        "phase1_country": "Republic of Korea",
        "phase1_start": 1592391600,
        "phase1_end": 1615982400,
        "phase1_trial": "NCT04445389",
        "phase2_country": "Republic of Korea",
        "phase2_start": 1592391600,
        "phase2_end": 1615982400,
        "phase2_trial": "NCT04445389",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$9,650,000.00",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 2,
        "phase0_start": 1584360000,
        "phase0_end": 1592391600,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584360000,
            1592391600,
            1592391600,
            0,
            0
        ],
        "end_dates": [
            1592391600,
            1615982400,
            1615982400,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "4",
        "institutes": "Immunomic Therapeutics\/Epivax\/PharmaJet",
        "country": "USA",
        "type": "Commercial",
        "name": "DNA vaccine",
        "platform": "DNA",
        "licenced": "none",
        "pipeline": "Epivax - BioDefence vaccines Pre-clinical, Phase I\nImmunomic - various DNA plasmid vaccines in development\n",
        "capacity": "none",
        "alliance": "Astellas Pharma https:\/\/www.immunomix.com\/\nhttps:\/\/epivax.com\/featured\/press-release-immunomic-therapeutics-forms-collaboration-with-epivax-and-pharmajet-to-develop-novel-vaccine-candidate-against-covid-19-using-its-investigational-unite-platform",
        "phase": "Pre-clinical",
        "start_date": 1586430000,
        "reference": "https:\/\/www.immunomix.com\/immunomic-therapeutics-forms-collaboration-with-epivax-and-pharmajet-to-develop-novel-vaccine-candidate-against-covid-19-using-its-investigational-unite-platform\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Plasmid DNA, needle-free delivery",
        "annual_revenue": "Immunomic Therapeutics $8M \nEpivax $3.31M \nPharmajet $11.56M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 3,
        "phase0_start": 1586430000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586430000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "5",
        "institutes": "Inovio Pharmaceuticals",
        "country": "USA",
        "type": "Commercial",
        "name": "INO-4800",
        "platform": "DNA",
        "licenced": "none",
        "pipeline": "HPV, HIV, Ebola, Lassa, Zika, MERS COVID-19 all Phase 2",
        "capacity": "contract manufacturers including VGXI, Inc., Richter-Helm, and Ology Biosciences to produce an anticipated one million doses of INO-4800 by year end and seeking additional external funding and partnerships to scale up manufacturing capacities to satisfy urgent global demand for a safe and effective vaccine.",
        "alliance": "https:\/\/www.inovio.com\/our-focus-serving-patients\/covid-19\/",
        "phase": "Phase I\/II",
        "start_date": 1584014400,
        "reference": "https:\/\/www.prnewswire.com\/news-releases\/inovio-receives-new-5-million-grant-to-accelerate-scale-up-of-smart-delivery-device-for-its-covid-19-vaccine-301022049.html",
        "phase1_country": "USA\nKorea",
        "phase1_start": 1585911600,
        "phase1_end": 1619780400,
        "phase1_trial": "NCT04336410\nNCT04447781",
        "phase2_country": "Republic of Korea",
        "phase2_start": 1592823600,
        "phase2_end": 1645531200,
        "phase2_trial": "NCT04447781",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "DNA plasmid vaccine electroporation device",
        "annual_revenue": "4.11M",
        "committed_doses": " -   ",
        "total_external_funding": " 29,100,000 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 4,
        "phase0_start": 1584014400,
        "phase0_end": 1585911600,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584014400,
            1585911600,
            1592823600,
            0,
            0
        ],
        "end_dates": [
            1585911600,
            1619780400,
            1645531200,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "6",
        "institutes": "Karolinska Intitute\/Cobra Biologics",
        "country": "Sweden",
        "type": "Commercial\/Academic",
        "name": "DNA vaccine",
        "platform": "DNA",
        "licenced": "none - mainly gene therapy DNA plasmid and Viral Vector products - no vaccines",
        "pipeline": "",
        "capacity": "AstraZenica to provide manufacturing capacity",
        "alliance": "AstraZenica.",
        "phase": "Pre-clinical",
        "start_date": 1585224000,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "DNA with electroporation",
        "annual_revenue": "$42.60M",
        "committed_doses": " -   ",
        "total_external_funding": " 3,421,965 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 5,
        "phase0_start": 1585224000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585224000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "7",
        "institutes": "Osaka University\/AnGes\/Takara Bio",
        "country": "Japan",
        "type": "Commercial\/Academic",
        "name": "DNA plasmid vaccine",
        "platform": "DNA",
        "licenced": "none",
        "pipeline": "AnGes - hypertention vaccine",
        "capacity": "",
        "alliance": "",
        "phase": "Phase I",
        "start_date": 1583409600,
        "reference": "https:\/\/www.anges.co.jp\/en\/pdf.php?pdf=003Mk7IxCg7spYu6nteDj80QPMCznRi2.pdf",
        "phase1_country": "Japan",
        "phase1_start": 1593428400,
        "phase1_end": 1601118000,
        "phase1_trial": "NCT04463472; JapicCTI-205328",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "AnGes $3.01M\nTakara $95.62M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 6,
        "phase0_start": 1583409600,
        "phase0_end": 1593428400,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583409600,
            1593428400,
            0,
            0,
            0
        ],
        "end_dates": [
            1593428400,
            1601118000,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 3
    },
    {
        "number": "8",
        "institutes": "Scancell\/University of Nottingham",
        "country": "UK",
        "type": "Commercial\/Academic",
        "name": "DNA vaccine",
        "platform": "DNA",
        "licenced": "none",
        "pipeline": "Cancer vaccines",
        "capacity": "none",
        "alliance": "University of Nottingham",
        "phase": "Pre-clinical",
        "start_date": 1587726000,
        "reference": "https:\/\/www.scancell.co.uk\/Data\/Sites\/1\/media\/publications\/news\/covid-19-vaccine-programme.pdf",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Target N and S proteins",
        "annual_revenue": "small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 7,
        "phase0_start": 1587726000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587726000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "9",
        "institutes": "Takis Biotech\/Evvivax\/Applied DNA Sciences",
        "country": "Italy\/USA",
        "type": "Commercial",
        "name": "DNA vaccine",
        "platform": "DNA",
        "licenced": "none",
        "pipeline": "Cancer vaccines",
        "capacity": "none",
        "alliance": "none identified",
        "phase": "Pre-clinical",
        "start_date": 1580126400,
        "reference": "http:\/\/www.takisbiotech.it\/index.php\/en\/news\/200-takis-and-evvivax-developing-a-2019-ncov-coronavirus-vaccine",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Takis $1.92M\nApplied  DNA Sciences $3.3M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 8,
        "phase0_start": 1580126400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1580126400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "10",
        "institutes": "University of Cambridge\/DIOSynVax",
        "country": "UK",
        "type": "Commercial\/Academic",
        "name": "DNA vaccine",
        "platform": "DNA",
        "licenced": "none",
        "pipeline": "DNA vaccines and DNA inserts",
        "capacity": "none",
        "alliance": "Innovate UK, Gates, U Cambridge",
        "phase": "Pre-clinical",
        "start_date": 1579262400,
        "reference": "https:\/\/www.cam.ac.uk\/research\/news\/cambridge-research-team-working-towards-vaccine-against-covid-19",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "sub 6.5 GBP",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 9,
        "phase0_start": 1579262400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1579262400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "11",
        "institutes": "Mediphage Bioceuticals, University of Waterloo",
        "country": "Canada",
        "type": "Academic",
        "name": "DNA vaccine",
        "platform": "DNA",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1587034800,
        "reference": "https:\/\/uwaterloo.ca\/stories\/news\/university-waterloo-developing-dna-based-covid-19-vaccine",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Nasal spray, bacteriophage delivery, VLP-encoded DNA vaccine",
        "annual_revenue": "accademic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 10,
        "phase0_start": 1587034800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587034800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "12",
        "institutes": "UW-Madison\/Pan Genomes Systems",
        "country": "USA",
        "type": "Commercial\/Academic",
        "name": "Unnamed vaccine",
        "platform": "DNA",
        "licenced": "Veterinary Vaccines",
        "pipeline": "Avian Carona Virus vaccine",
        "capacity": "none",
        "alliance": "U Wisconson - Madison House",
        "phase": "Pre-clinical",
        "start_date": 1581768000,
        "reference": "https:\/\/www.trialsitenews.com\/uw-madison-spinoff-purses-covid-19-vaccine-introducing-pan-genome-systems\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Nasal spray; nucleic acid based",
        "annual_revenue": "$6M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 11,
        "phase0_start": 1581768000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1581768000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "13",
        "institutes": "Zydus Cadila (DNA vaccine)",
        "country": "India",
        "type": "Commercial",
        "name": "DNA plasmid vaccine",
        "platform": "DNA",
        "licenced": "Influenza Vaccine -VaxiFlu\nTyphoid",
        "pipeline": "Diphtheria, Pertussis, Tetanus, Haemophilus Influenzae type B, Hepatitis B, Measles, Mumps, Rubella, Varicella, Influenza",
        "capacity": "Vaccine Technology Centre - capacity not known",
        "alliance": "none identified",
        "phase": "Phase I\/II",
        "start_date": 1584705600,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/novel-coronavirus-landscape-ncov.pdf?ua=1",
        "phase1_country": "India",
        "phase1_start": 1594638000,
        "phase1_end": 0,
        "phase1_trial": "CTRI\/2020\/07\/026352\u00a0",
        "phase2_country": "India",
        "phase2_start": 1594638000,
        "phase2_end": 0,
        "phase2_trial": "CTRI\/2020\/07\/026352\u00a0",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$1.9B",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 12,
        "phase0_start": 1584705600,
        "phase0_end": 1594638000,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584705600,
            1594638000,
            1594638000,
            0,
            0
        ],
        "end_dates": [
            1594638000,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 3
    },
    {
        "number": "14",
        "institutes": "Symvivo",
        "country": "Canada",
        "type": "Commercial",
        "name": "bacTRL-Spike",
        "platform": "DNA",
        "licenced": "none+G74G63G63:G64",
        "pipeline": "oncology, DNA vaccines in pre-clinical",
        "capacity": "none",
        "alliance": "none identified",
        "phase": "Phase I",
        "start_date": 1586170800,
        "reference": "https:\/\/www.symvivo.com\/covid-19",
        "phase1_country": "Canada",
        "phase1_start": 1588244400,
        "phase1_end": 1630407600,
        "phase1_trial": "NCT04334980",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Orally administered, genetically modified probiotic bacteria",
        "annual_revenue": "$580,698 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 13,
        "phase0_start": 1586170800,
        "phase0_end": 1588244400,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586170800,
            1588244400,
            0,
            0,
            0
        ],
        "end_dates": [
            1588244400,
            1630407600,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "15",
        "institutes": "BioNet Asia",
        "country": "Thailand",
        "type": "Commercial",
        "name": "Unnamed vaccine",
        "platform": "DNA",
        "licenced": "DPT, Tetanus, Diphtheria, Hib, Pentavalent, Influenza, JEV, Measles, Rabies, Polio",
        "pipeline": "Dengue, Zika, HPV, COVID-19 Preclinical",
        "capacity": "Full scale vaccine manufacturing - capacity unknown",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1585224000,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$44m",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 14,
        "phase0_start": 1585224000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585224000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "16",
        "institutes": "City of Hope",
        "country": "USA",
        "type": "Academic",
        "name": "Unnamed vaccine",
        "platform": "DNA",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "Yes but capacity unknown",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1585051200,
        "reference": "https:\/\/www.cityofhope.org\/breakthroughs\/city-of-hope-researchers-developing-covid-19-vaccine",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 15,
        "phase0_start": 1585051200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585051200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "220",
        "institutes": "Chula Vaccine Research Centre",
        "country": "Thailand",
        "type": "Academic",
        "name": "DNA with electroporation",
        "platform": "DNA",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1595847600,
        "reference": "https:\/\/covid-19tracker.milkeninstitute.org\/#vaccines_intro",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 16,
        "phase0_start": 1595847600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1595847600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "221",
        "institutes": "Statens Serum Institute",
        "country": "Denmark",
        "type": "",
        "name": "CoVAXIX",
        "platform": "DNA",
        "licenced": "none",
        "pipeline": "tuberculosis, HIV, Chlamydia, Malaria and pandemic influenza\nrecombinant protein or DNA",
        "capacity": "Yes - capacity unknown",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 0,
        "reference": "https:\/\/en.ssi.dk\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 17,
        "phase0_start": 0,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 6,
        "funding_key": 4
    },
    {
        "number": "17",
        "institutes": "Beijing Institute of Biological Products\/Wuhan Institute of Biological Products\/Sinopharm",
        "country": "China",
        "type": "Academic",
        "name": "Inactivated vaccine",
        "platform": "Inactivated",
        "licenced": "JE vac and maybe others",
        "pipeline": "not known",
        "capacity": "Production capability for biologicals and vaccines but capacity unknown",
        "alliance": "BIBP",
        "phase": "Phase I\/II\/III",
        "start_date": 1585224000,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF",
        "phase1_country": "China",
        "phase1_start": 1586602800,
        "phase1_end": 1636545600,
        "phase1_trial": "ChiCTR2000031809 ",
        "phase2_country": "China",
        "phase2_start": 1588071600,
        "phase2_end": 1638100800,
        "phase2_trial": "ChiCTR2000032459",
        "phase3_country": "UAE\nUAE",
        "phase3_start": 1594897200,
        "phase3_end": 1626346800,
        "phase3_trial": "ChiCTR2000034780\n   NCT04510207",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 141,858,057 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Some external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 18,
        "phase0_start": 1585224000,
        "phase0_end": 1586602800,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585224000,
            1586602800,
            1588071600,
            1594897200,
            0
        ],
        "end_dates": [
            1586602800,
            1636545600,
            1638100800,
            1626346800,
            0
        ],
        "platform_key": 2,
        "funding_key": 1
    },
    {
        "number": "18",
        "institutes": "Beijing Minhai Biotechnology Co",
        "country": "China",
        "type": "Commercial",
        "name": "Inactivated vaccine",
        "platform": "Inactivated",
        "licenced": "Hib, Measles Rubella",
        "pipeline": "not known",
        "capacity": "Manufacturing capacity not known",
        "alliance": "",
        "phase": "Pre-clinical",
        "start_date": 1590577200,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$11M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 19,
        "phase0_start": 1590577200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1590577200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 2,
        "funding_key": 4
    },
    {
        "number": "19",
        "institutes": "Institute of Medical Biology,\/ Chinese Academy of Medical Sciences",
        "country": "China",
        "type": "Academic",
        "name": "Inactivated vaccine",
        "platform": "Inactivated",
        "licenced": "unknown  ",
        "pipeline": "unknown  ",
        "capacity": "unknown  ",
        "alliance": "unknown  ",
        "phase": "Phase I\/II",
        "start_date": 1587121200,
        "reference": "https:\/\/www.biocentury.com\/article\/304515",
        "phase1_country": "China\nChina",
        "phase1_start": 1589540400,
        "phase1_end": 1601463600,
        "phase1_trial": "NCT04412538\nNCT04470609",
        "phase2_country": "China\nChina",
        "phase2_start": 1588071600,
        "phase2_end": 1638100800,
        "phase2_trial": "ChiCTR2000032459\nNCT04470609",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 20,
        "phase0_start": 1587121200,
        "phase0_end": 1589540400,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587121200,
            1589540400,
            1588071600,
            0,
            0
        ],
        "end_dates": [
            1589540400,
            1601463600,
            1638100800,
            0,
            0
        ],
        "platform_key": 2,
        "funding_key": 4
    },
    {
        "number": "20",
        "institutes": "Osaka University\/BIKEN\/NIBIOHN (inactivated)",
        "country": "Japan",
        "type": "Commercial\/Academic",
        "name": "Inactivated vaccine",
        "platform": "Inactivated",
        "licenced": "Biken - Var, MR, Flu, DPT & Polio",
        "pipeline": "not known",
        "capacity": "Biken has manufacturing - unknown capacity",
        "alliance": "",
        "phase": "Pre-clinical",
        "start_date": 1584619200,
        "reference": "https:\/\/pj.jiho.jp\/article\/241725",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "BIKEN $333.20M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 21,
        "phase0_start": 1584619200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584619200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 2,
        "funding_key": 3
    },
    {
        "number": "21",
        "institutes": "Research Institute for\/ Biological Safety Problems",
        "country": "Republic of Kazakhstan",
        "type": "Academic",
        "name": "Inactivated vaccine",
        "platform": "Inactivated",
        "licenced": "unknown  ",
        "pipeline": "unknown  ",
        "capacity": "unknown  ",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1589540400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 22,
        "phase0_start": 1589540400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1589540400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 2,
        "funding_key": 4
    },
    {
        "number": "22",
        "institutes": "Sinovac",
        "country": "China",
        "type": "Commercial",
        "name": "Inactivated vaccine",
        "platform": "Inactivated",
        "licenced": "Hep A, Hep B, Influenza, Eterovirus 17",
        "pipeline": "Sabin Polio, Pneumococcal conjugate, Influenza, ",
        "capacity": "production facilities - capacity not known",
        "alliance": "unknown  ",
        "phase": "Phase III",
        "start_date": 1584705600,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/novel-coronavirus-landscape-ncov.pdf?ua=1",
        "phase1_country": "China",
        "phase1_start": 1587034800,
        "phase1_end": 1597316400,
        "phase1_trial": "NCT04352608\/ NCT04383574",
        "phase2_country": "China",
        "phase2_start": 1587034800,
        "phase2_end": 1597316400,
        "phase2_trial": "NCT04352608",
        "phase3_country": "Brazil\nIndonesia",
        "phase3_start": 1593601200,
        "phase3_end": 1632999600,
        "phase3_trial": "NCT04456595\nNCT04508075",
        "other": "Formaldehyde-inactivated + alum",
        "annual_revenue": "$246.1M",
        "committed_doses": " 370,000,000 ",
        "total_external_funding": " 15,000,000 ",
        "firm_size": "Medium Pharma",
        "funding_category": "Large external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 23,
        "phase0_start": 1584705600,
        "phase0_end": 1587034800,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584705600,
            1587034800,
            1587034800,
            1593601200,
            0
        ],
        "end_dates": [
            1587034800,
            1597316400,
            1597316400,
            1632999600,
            0
        ],
        "platform_key": 2,
        "funding_key": 0
    },
    {
        "number": "23",
        "institutes": "Sinovac\/Dynavax",
        "country": "China",
        "type": "Commercial",
        "name": "Inactivated vaccine",
        "platform": "Inactivated",
        "licenced": "Hep A, Hep B, Influenza, Eterovirus 17",
        "pipeline": "Sabin Polio, Pneumococcal conjugate, Influenza, ",
        "capacity": "production facilities - capacity not known",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1587034800,
        "reference": "https:\/\/www.globenewswire.com\/news-release\/2020\/04\/16\/2017222\/0\/en\/Dynavax-and-Sinovac-Announce-Collaboration-to-Develop-a-Coronavirus-COVID-19-Vaccine.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Sinovac\u2019s inactivated vaccine plus Dynavax adjuvant CpG 1018 adjuvant",
        "annual_revenue": "Sinovac $246.1M  Dynavax $29.1M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 24,
        "phase0_start": 1587034800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587034800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 2,
        "funding_key": 3
    },
    {
        "number": "24",
        "institutes": "Valneva\/Dynavax",
        "country": "France",
        "type": "Commercial",
        "name": "Inactivated vaccine",
        "platform": "Inactivated",
        "licenced": "JEV Cholera",
        "pipeline": "Lyme, Chikungunia, Zika, C diff",
        "capacity": "Yes but details not known",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1587553200,
        "reference": "https:\/\/valneva.com\/press-release\/valneva-and-dynavax-announce-collaboration-to-advance-vaccine-development-for-covid-19\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Valneva $156.4M",
        "committed_doses": " 60,000,000 ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Some external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 25,
        "phase0_start": 1587553200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587553200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 2,
        "funding_key": 1
    },
    {
        "number": "194",
        "institutes": "Bharat Biotech National Institute of Virology",
        "country": "India",
        "type": "Commercial",
        "name": "Covaxin",
        "platform": "Inactivated",
        "licenced": "DPT combinations, Polio, Influenza, Rabies, Rota, JE, S typhi",
        "pipeline": "Chickungunya, Zika, HPV, Malaria",
        "capacity": "Yes - full scale vaccine manufacturing - largest in Asia Pacific",
        "alliance": "Gates, CDC, NIH, NIAID, Govt of India ",
        "phase": "Phase I\/II",
        "start_date": 1594638000,
        "reference": "New addition to LSHTM list of candidates July 28, 2020",
        "phase1_country": "India",
        "phase1_start": 1594638000,
        "phase1_end": 1625050800,
        "phase1_trial": "CTRI\/2020\/07\/026300;\nNCT04471519",
        "phase2_country": "India",
        "phase2_start": 1594638000,
        "phase2_end": 1625050800,
        "phase2_trial": "CTRI\/2020\/07\/026300;\nNCT04471519",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$6.7m",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 26,
        "phase0_start": 1594638000,
        "phase0_end": 1594638000,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1594638000,
            1594638000,
            1594638000,
            0,
            0
        ],
        "end_dates": [
            1594638000,
            1625050800,
            1625050800,
            0,
            0
        ],
        "platform_key": 2,
        "funding_key": 4
    },
    {
        "number": "25",
        "institutes": "Codagenix\/Serum Institute of India",
        "country": "USA\/India",
        "type": "Commercial",
        "name": "Live-attenuated vaccine",
        "platform": "Live-attenuated",
        "licenced": "None",
        "pipeline": "HAV, InfA, ZIKV, FMD, SIV, RSV,\nDENV",
        "capacity": "Serunm Institute of India has multiple vaccine manufacturing facilites - FDA approved - capacity unknown",
        "alliance": "https:\/\/www.seruminstitute.com\/index.php\nhttps:\/\/codagenix.com\/",
        "phase": "Pre-clinical",
        "start_date": 1581595200,
        "reference": "https:\/\/www.prnewswire.com\/news-releases\/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html?tc=eml_cleartime",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Deoptimized live attanuated",
        "annual_revenue": "Codagenix $982302 \nSerum Institute of India $595M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 27,
        "phase0_start": 1581595200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1581595200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 0,
        "funding_key": 3
    },
    {
        "number": "27",
        "institutes": "Indian Immunologicals Ltd\/Griffith University",
        "country": "India\/USA",
        "type": "Commercial\/Academic",
        "name": "Live-attenuated vaccine",
        "platform": "Live-attenuated",
        "licenced": "None",
        "pipeline": "None",
        "capacity": "None",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1587639600,
        "reference": "https:\/\/news.griffith.edu.au\/2020\/04\/23\/griffith-university-researchers-on-the-road-to-covid-19-vaccine\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Codon deoptimized live attenuated virus",
        "annual_revenue": "$32M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 28,
        "phase0_start": 1587639600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587639600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 0,
        "funding_key": 4
    },
    {
        "number": "28",
        "institutes": "Shenzhen Geno-Immune Medical Institute\/(modified DC)",
        "country": "China",
        "type": "Academic",
        "name": "LV-SMENP-DC vaccine\nmodified HIV viral vector",
        "platform": "Non-replicating viral vector",
        "licenced": "none - relatively new organization",
        "pipeline": "CART-T, Cancer vaccines, Immunotherapy",
        "capacity": "Unknown - through partnerships",
        "alliance": "foreign academic institutes, many chinese partners, some capable of manufacturing",
        "phase": "Phase I",
        "start_date": 1580472000,
        "reference": "https:\/\/www.nature.com\/articles\/d41573-020-00073-5",
        "phase1_country": "China",
        "phase1_start": 1585051200,
        "phase1_end": 1690801200,
        "phase1_trial": "NCT04276896",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "DCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific CTLs",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 29,
        "phase0_start": 1580472000,
        "phase0_end": 1585051200,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1580472000,
            1585051200,
            0,
            0,
            0
        ],
        "end_dates": [
            1585051200,
            1690801200,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "29",
        "institutes": "Altimmune",
        "country": "USA",
        "type": "Commercial",
        "name": "T-COVID",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "Intranasal Vaccines - Anthrax, Influenza Phase 1 & 2",
        "capacity": "None",
        "alliance": "Not known",
        "phase": "Phase I",
        "start_date": 1591009200,
        "reference": "https:\/\/www.globenewswire.com\/news-release\/2020\/06\/01\/2041361\/0\/en\/Altimmune-Launches-Clinical-Trial-of-T-COVIDTM-an-Investigational-Intranasal-Immune-Modulator-for-the-Treatment-of-Patients-with-Early-COVID-19.html",
        "phase1_country": "01\/06\/2020",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "Announced",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Adenovirus-based NasoVAX",
        "annual_revenue": "5.8M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 30,
        "phase0_start": 1591009200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "30",
        "institutes": "Altimmune\/University of Alabama at Birmingham",
        "country": "USA",
        "type": "Commercial",
        "name": "AdCOVID",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "Intranasal Vaccines - Anthrax, Influenza Phase 1 & 2",
        "capacity": "None",
        "alliance": "Not known",
        "phase": "Pre-clinical",
        "start_date": 1582891200,
        "reference": "https:\/\/www.globenewswire.com\/news-release\/2020\/02\/28\/1992600\/0\/en\/Altimmune-Completes-First-Development-Milestone-Toward-a-Single-Dose-Intranasal-COVID-19-Vaccine.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Adenovirus-based NasoVAX expressing SARS2-CoV spike protein",
        "annual_revenue": "5.8m",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 31,
        "phase0_start": 1582891200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1582891200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "31",
        "institutes": "CanSino Biological Inc\/Beijing Institute of Biotechnology",
        "country": "China",
        "type": "Commercial\/Academic",
        "name": "Ad5-nCoV",
        "platform": "Non-replicating viral vector",
        "licenced": "Ebola",
        "pipeline": "meningitis, pneumonia, tuberculosis, COVID-19,\u00a0Ebola virus disease, pertussis, diphtheria, tetanus, shingles",
        "capacity": "pilot plant + commercial manufacturing 70 million to 80 million doses cGMP approved FDA, EU, WHO and China",
        "alliance": "unknown  ",
        "phase": "Phase I\/II",
        "start_date": 1579521600,
        "reference": "https:\/\/www.bioworld.com\/articles\/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials",
        "phase1_country": "China\n\nCanada",
        "phase1_start": 1584360000,
        "phase1_end": 1609329600,
        "phase1_trial": "ChiCTR2000030906\/ NCT04313127  NCT04398147",
        "phase2_country": "China\n\nCanada",
        "phase2_start": 1586689200,
        "phase2_end": 1612094400,
        "phase2_trial": "ChiCTR2000031781\/ NCT04341389  NCT04398147",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "revenue figures hard to find but given bn market cap should be medium",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 32,
        "phase0_start": 1579521600,
        "phase0_end": 1584360000,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1579521600,
            1584360000,
            1586689200,
            0,
            0
        ],
        "end_dates": [
            1584360000,
            1609329600,
            1612094400,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 3
    },
    {
        "number": "32",
        "institutes": "CNB-CSIC (viral vector)",
        "country": "Spain",
        "type": "Academic",
        "name": "Non-replicating viral vector vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1585224000,
        "reference": "https:\/\/fems-microbiology.org\/wp-content\/uploads\/2020\/03\/Enjuanes-Sola-Z\u00fa\u00f1iga-2020.-Novel-Human-Pathogenic-Coronavirus-SARS-CoV-2.pdf",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "MVA expressing structural proteins",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 5,578,772 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 33,
        "phase0_start": 1585224000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585224000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "33",
        "institutes": "DZIF - German Center for Infection\/Research (viral vector)",
        "country": "Germany",
        "type": "Academic",
        "name": "MVA-S encoded vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "multiple institutions",
        "phase": "Pre-clinical",
        "start_date": 1586602800,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "MVA-S encoded",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 34,
        "phase0_start": 1586602800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586602800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "34",
        "institutes": "Gamaleya Research Institute",
        "country": "Russia",
        "type": "Academic",
        "name": "Gam-COVID-Vac",
        "platform": "Non-replicating viral vector",
        "licenced": "no data",
        "pipeline": "no data",
        "capacity": "no data",
        "alliance": "no data",
        "phase": "Phase I",
        "start_date": 1591009200,
        "reference": "https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "Russia",
        "phase1_start": 1592391600,
        "phase1_end": 1596625200,
        "phase1_trial": "NCT04436471; NCT04437875",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "rAd26\/rAd5 expressing S protein, intramuscular, separate trial of lyophilised formulation",
        "annual_revenue": "Academic",
        "committed_doses": " 50,000,000 ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Some external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 35,
        "phase0_start": 1591009200,
        "phase0_end": 1592391600,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            1592391600,
            0,
            0,
            0
        ],
        "end_dates": [
            1592391600,
            1596625200,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 1
    },
    {
        "number": "35",
        "institutes": "GeoVax\/BravoVax",
        "country": "China",
        "type": "Commercial",
        "name": "MVA-VLP vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "None",
        "pipeline": "HIV, Lassa, Marburg, Ebola, Sudan, Zika, Malaria, Hep B mostly pre-clinical some Phase I or II",
        "capacity": "BravoVax has pilot production facilities",
        "alliance": "GeoVax platform BravoVax manufacturing support and contacts into China",
        "phase": "Pre-clinical",
        "start_date": 1580126400,
        "reference": "https:\/\/www.geovax.com\/news\/geovax-and-bravovax-wuhan-china-to-collaborate-on-development-of-coronavirus-vaccine",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "MVA-encoded VLP",
        "annual_revenue": "Geovax $1.18M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 36,
        "phase0_start": 1580126400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1580126400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "36",
        "institutes": "Greffex",
        "country": "USA",
        "type": "Commercial",
        "name": "Ad5 S (GREVAX)",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1583928000,
        "reference": "https:\/\/www.greffex.com\/news\/greffex-inc-completes-covid-19-vaccine-and-prepares-for-testing\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Ad5 S (GREVAX platform)",
        "annual_revenue": "$950,000 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 37,
        "phase0_start": 1583928000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583928000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "37",
        "institutes": "IDIBAPS-Hospital Clinic (viral vector)",
        "country": "Spain",
        "type": "Commercial",
        "name": "MVA-S vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "Consortium of research hospitals in Europe",
        "phase": "Pre-clinical",
        "start_date": 1591009200,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "5.9",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 38,
        "phase0_start": 1591009200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "38",
        "institutes": "ImmunityBio\/NantKwest",
        "country": "USA",
        "type": "Commercial",
        "name": "hAd5-COVID19-Spike\/Nucleocapsid",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "mostly cancer therapies",
        "capacity": "NantKwest manufacturing facility",
        "alliance": "Warp Speed candidate",
        "phase": "Pre-clinical",
        "start_date": 1586862000,
        "reference": "https:\/\/www.biospace.com\/article\/releases\/nantkwest-and-immunitybio-announce-therapeutics-and-vaccines-for-combatting-covid-19-clinical-trials-anticipated-to-begin-this-quarter\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Four deletions enabling response in Ad-exposed",
        "annual_revenue": "ImmunityBio $13M NantKwest $43,000",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 39,
        "phase0_start": 1586862000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586862000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "39",
        "institutes": "Johnson & Johnson  (Janssen)",
        "country": "USA",
        "type": "Commercial",
        "name": "Ad26 vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "Ebola, HIV Phase III",
        "capacity": "yes but capacity not known",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1580126400,
        "reference": "https:\/\/www.cnbc.com\/2020\/01\/27\/jj-pretty-confident-it-can-create-china-coronavirus-vaccine.html",
        "phase1_country": "Japan",
        "phase1_start": 1597143600,
        "phase1_end": 1610107200,
        "phase1_trial": "NCT04509947",
        "phase2_country": "Belgium,USA",
        "phase2_start": 1594810800,
        "phase2_end": 1631703600,
        "phase2_trial": "NCT04436276",
        "phase3_country": "USA,Brazil,Chila,Colombia, Mexico,Peru,Philippines,South Africa, Ukraine",
        "phase3_start": 1599303600,
        "phase3_end": 1678449600,
        "phase3_trial": "NCT04505722",
        "other": "Ad26 (alone or with MVA boost)",
        "annual_revenue": "$82.11 B",
        "committed_doses": " 330,000,000 ",
        "total_external_funding": " 456,237,081 ",
        "firm_size": "large pharma",
        "funding_category": "Large external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 40,
        "phase0_start": 1580126400,
        "phase0_end": 1597143600,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1580126400,
            1597143600,
            1594810800,
            1599303600,
            0
        ],
        "end_dates": [
            1597143600,
            1610107200,
            1631703600,
            1678449600,
            0
        ],
        "platform_key": 4,
        "funding_key": 0
    },
    {
        "number": "40",
        "institutes": "Massachusetts Eye and Ear\/Massachusetts General Hospital",
        "country": "USA",
        "type": "Academic",
        "name": "AAVCOVID",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "Manufacturing started March 2020 (Research Grade Manufacturing), May 2020 (Clinical Grade Manufacturing)\nConsortium Partner Novartis\/AveXis - 100 million doses\nscale up completed",
        "alliance": "Consortium Partner Novartis\/AveXis\n$5 millioin USD",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/masseyeandear.org\/news\/press-releases\/2020\/05\/mee-and-mgh-advancing-aavcovid-vaccine",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "adeno-associated viral (AAV)-based, S protein\nanticipate license Q3 2021",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 41,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "41",
        "institutes": "Massachusetts General Hospital\/Grousbeck Gene Therapy Center\/AveXis",
        "country": "USA",
        "type": "Commercial\/Academic",
        "name": "AAVCOVID",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "gene therapies - no vaccines",
        "capacity": "none",
        "alliance": "Mass Gen Hospital and AveXis Ltd.",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.newswise.com\/coronavirus\/massachusetts-eye-and-ear-and-massachusetts-general-hospital-advancing-novel-experimental-gene-based-covid-19-vaccine-aavcovid\/?article_id=731068",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Adeno-associated viral vector (AAV), spike protein",
        "annual_revenue": "AveXis$203.1M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 42,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 3
    },
    {
        "number": "42",
        "institutes": "McMaster University",
        "country": "Canada",
        "type": "Academic",
        "name": "Non-replicating viral vector vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1590490800,
        "reference": "Direct contact",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 1,421,624 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 43,
        "phase0_start": 1590490800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1590490800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "43",
        "institutes": "National Center for Genetic Engineering & Biotechnology (BIOTEC)\/GPO",
        "country": "Thailand",
        "type": "Commercial\/Academic",
        "name": "Non-replicating viral vector vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1591009200,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Multi-valent HuAd5 and ChAd68-vectored; aerosol delivery",
        "annual_revenue": "can't find",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 44,
        "phase0_start": 1591009200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "44",
        "institutes": "ReiThera\/Leukocare\/Univercells",
        "country": "Italy",
        "type": "Commercial",
        "name": "Non-replicating viral vector vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "Polio, Measles, Rubella, Rabies",
        "capacity": "Univercells 50 million doses polio vaccine\/yr",
        "alliance": "unknown  ",
        "phase": "Phase I",
        "start_date": 1585224000,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF",
        "phase1_country": "Italy",
        "phase1_start": 1598266800,
        "phase1_end": 0,
        "phase1_trial": "2020-002835-31",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant",
        "annual_revenue": "ReiThera $16.27M Univercells $1.66M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 45,
        "phase0_start": 1585224000,
        "phase0_end": 1598266800,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585224000,
            1598266800,
            0,
            0,
            0
        ],
        "end_dates": [
            1598266800,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "45",
        "institutes": "Stabilitech",
        "country": "UK",
        "type": "Commercial",
        "name": "OraPro-COVID-19",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "Zika ",
        "capacity": "none",
        "alliance": "GSK, Pfizer animal health",
        "phase": "Pre-clinical",
        "start_date": 1584619200,
        "reference": "https:\/\/www.stabilitech.com\/orapro-covid-19\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S",
        "annual_revenue": "$166,899 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 46,
        "phase0_start": 1584619200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584619200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "46",
        "institutes": "Tsinghua University",
        "country": "China",
        "type": "Academic",
        "name": "Adenovirus-vectored vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1585825200,
        "reference": "http:\/\/www.china.org.cn\/china\/2020-04\/02\/content_75891534.htm",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Orally administered recombinant adenovirus vector",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 47,
        "phase0_start": 1585825200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585825200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "47",
        "institutes": "University of Georgia\/University of Iowa",
        "country": "USA",
        "type": "Academic",
        "name": "Non-replicating viral vector vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Adenovirus vector-based vaccine (could not verify if replicating\/non-replicating)",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 48,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "48",
        "institutes": "University of Manitoba",
        "country": "Canada",
        "type": "Academic",
        "name": "Dendritic cell-based vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "Canadian Govt funding $600K",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Parainfluenza virus 5-based vaccine expressing S protein",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 421,902 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 49,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "49",
        "institutes": "University of Oxford\/AstraZeneca",
        "country": "UK",
        "type": "Commercial\/Academic",
        "name": "AZD1222\/ChAdOx1-S",
        "platform": "Non-replicating viral vector",
        "licenced": "Influenza Vaccine - Flumist",
        "pipeline": "Astra Zenica pipeline",
        "capacity": "AstraZenica, Catalent (Italy), Oxford Biomedica (new), Serum Institute of India through IVA\n2 billion doses\/yr with combined manufacturing of Serum Institute of India - 400 million for Europe",
        "alliance": "AstraZenica, Catalent (Italy), Oxford Biomedica, Oxford, IVA, GAVI, Serum Institute of India",
        "phase": "Phase I\/II\/III",
        "start_date": 1578657600,
        "reference": "https:\/\/www.ovg.ox.ac.uk\/news\/covid-19-vaccine-development",
        "phase1_country": "UK\n\nSouth Africa",
        "phase1_start": 1587639600,
        "phase1_end": 1622458800,
        "phase1_trial": "NCT04324606\/ EudraCT2020-001072-15  NCT04444674",
        "phase2_country": "UK\n\nSouth Africa",
        "phase2_start": 1588330800,
        "phase2_end": 1630407600,
        "phase2_trial": "NCT04400838\/ EudraCT2020-001228-32 NCT04444674",
        "phase3_country": "UK\nBrazil\nUSA",
        "phase3_start": 1590663600,
        "phase3_end": 1630407600,
        "phase3_trial": "NCT04400838\nISRCTN89951424\nNCT04516746",
        "other": "",
        "annual_revenue": "$24.4B",
        "committed_doses": " 2,400,000,000 ",
        "total_external_funding": " 106,751,299 ",
        "firm_size": "large pharma",
        "funding_category": "Large external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 50,
        "phase0_start": 1578657600,
        "phase0_end": 1587639600,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1578657600,
            1587639600,
            1588330800,
            1590663600,
            0
        ],
        "end_dates": [
            1587639600,
            1622458800,
            1630407600,
            1630407600,
            0
        ],
        "platform_key": 4,
        "funding_key": 0
    },
    {
        "number": "50",
        "institutes": "Valo Therapeutics Ltd",
        "country": "Finland\/USA",
        "type": "Commercial",
        "name": "Pan-Corona",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Chimpanzee adenovirus vector",
        "annual_revenue": "$253,700 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 51,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "51",
        "institutes": "Vaxart\/Emergent Biosolutions",
        "country": "USA",
        "type": "Commercial",
        "name": "Oral recombinant vaccine",
        "platform": "Non-replicating viral vector",
        "licenced": "none",
        "pipeline": "Norovirus, Influenza, RSV Pre-clinical or Phase I",
        "capacity": "none",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1584532800,
        "reference": "http:\/\/www.globenewswire.com\/news-release\/2020\/03\/18\/2002458\/0\/en\/EMERGENT-BIOSOLUTIONS-SIGNS-DEVELOPMENT-AND-MANUFACTURING-AGREEMENT-WITH-VAXART-FOR-THEIR-EXPERIMENTAL-ORAL-VACCINE-CANDIDATE-FOR-CORONAVIRUS-DISEASE.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Adenovirus-based + HLA-matched peptides",
        "annual_revenue": "Vaxart $9.9M\nEmergent Biosolutions $270.7M\n",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 52,
        "phase0_start": 1584532800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584532800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 4,
        "funding_key": 4
    },
    {
        "number": "52",
        "institutes": "Aivita Biomedical Inc",
        "country": "USA",
        "type": "Commercial",
        "name": "AV-COVID-19",
        "platform": "Other",
        "licenced": "none",
        "pipeline": "Cancer immunotherapy",
        "capacity": "none",
        "alliance": "none",
        "phase": "Phase I",
        "start_date": 1589367600,
        "reference": "https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04386252?term=vaccine&cond=COVID-19&draw=2&rank=18",
        "phase1_country": "USA",
        "phase1_start": 1593601200,
        "phase1_end": 1609416000,
        "phase1_trial": "NCT04386252",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$11M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 53,
        "phase0_start": 1589367600,
        "phase0_end": 1593601200,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1589367600,
            1593601200,
            0,
            0,
            0
        ],
        "end_dates": [
            1593601200,
            1609416000,
            0,
            0,
            0
        ],
        "platform_key": 7,
        "funding_key": 4
    },
    {
        "number": "53",
        "institutes": "ERC Worldwide",
        "country": "Belgium",
        "type": "Commercial",
        "name": "ERC SARS-Cov-2 vaccine",
        "platform": "Other",
        "licenced": "Cancer vaccine - Gliovac",
        "pipeline": "cancer vaccines, Ebola",
        "capacity": "yes - capacity unknown  ",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1586430000,
        "reference": "https:\/\/finance.yahoo.com\/news\/erc-launches-development-program-novel-120010871.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "unknown",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 54,
        "phase0_start": 1586430000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586430000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 7,
        "funding_key": 4
    },
    {
        "number": "54",
        "institutes": "Immunitor Inc",
        "country": "Canada",
        "type": "Commercial",
        "name": "V-SARS inactivated plasma",
        "platform": "Other",
        "licenced": "therapeutics",
        "pipeline": "Therapeutic antibodies & proteins",
        "capacity": "unknown  ",
        "alliance": "unknown  ",
        "phase": "Phase I",
        "start_date": 1588935600,
        "reference": "https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04380532?term=NCT04380532&draw=1&rank=1",
        "phase1_country": "Canada",
        "phase1_start": 1592218800,
        "phase1_end": 1621076400,
        "phase1_trial": "NCT04380532",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Consists of virions at different stages of viral replication and human cells\/fragments",
        "annual_revenue": "$1M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 55,
        "phase0_start": 1588935600,
        "phase0_end": 1592218800,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588935600,
            1592218800,
            0,
            0,
            0
        ],
        "end_dates": [
            1592218800,
            1621076400,
            0,
            0,
            0
        ],
        "platform_key": 7,
        "funding_key": 4
    },
    {
        "number": "56",
        "institutes": "Shenzhen Geno-Immune Medical Institute\/(modified APC)",
        "country": "China",
        "type": "Academic",
        "name": "aAPC vaccine",
        "platform": "Other",
        "licenced": "none - relatively new organization",
        "pipeline": "CART-T, Cancer vaccines, Immunotherapy",
        "capacity": "Unknown - through partnerships",
        "alliance": "foreign academic institutes, many chinese partners, some capable of manufacturing",
        "phase": "Phase I",
        "start_date": 1580472000,
        "reference": "https:\/\/www.nature.com\/articles\/d41573-020-00073-5",
        "phase1_country": "China",
        "phase1_start": 1581768000,
        "phase1_end": 1690801200,
        "phase1_trial": "NCT04299724",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "ADDomer multiepitope display",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 56,
        "phase0_start": 1580472000,
        "phase0_end": 1581768000,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1580472000,
            1581768000,
            0,
            0,
            0
        ],
        "end_dates": [
            1581768000,
            1690801200,
            0,
            0,
            0
        ],
        "platform_key": 7,
        "funding_key": 4
    },
    {
        "number": "57",
        "institutes": "University of California, Los Angeles",
        "country": "USA",
        "type": "Academic",
        "name": "Replicating bacterial vector vaccine",
        "platform": "Other",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1588330800,
        "reference": "http:\/\/ucla.technologypublisher.com\/techcase\/20-0322",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Artificial APCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 57,
        "phase0_start": 1588330800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588330800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 7,
        "funding_key": 4
    },
    {
        "number": "58",
        "institutes": "Versatope\/Umass (OMV)",
        "country": "USA",
        "type": "Commercial\/Academic",
        "name": "rOMV vaccine",
        "platform": "Other",
        "licenced": "none",
        "pipeline": "Influenza, COVID-19,",
        "capacity": "none",
        "alliance": "NIAIH funding for Influenza, Umass",
        "phase": "Pre-clinical",
        "start_date": 1585566000,
        "reference": "https:\/\/www.uml.edu\/News\/stories\/2020\/M2D2-coronavirus-efforts.aspx?mc_cid=b01e8bd49c&mc_eid=565cb5181a",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Recombinant LVS \u0394capB \u2013 vectored vaccine expressing multiple SARS-CoV-2 antigens.",
        "annual_revenue": "$92,591 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 58,
        "phase0_start": 1585566000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585566000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 7,
        "funding_key": 4
    },
    {
        "number": "55",
        "institutes": "Imophoron Ltd\/Bristol University",
        "country": "UK",
        "type": "Commercial\/Academic",
        "name": "ADDomer VLP vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "Insect based Influenza VLP vaccine",
        "capacity": "unknown  ",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1583668800,
        "reference": "https:\/\/www.pharmaceutical-technology.com\/news\/bristol-university-imophoron-covid-vaccine\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Inactivated plasma vaccine; once-daily pill",
        "annual_revenue": "101142",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 59,
        "phase0_start": 1583668800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583668800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "59",
        "institutes": "ARTES Biotechnology",
        "country": "Germany",
        "type": "Commercial",
        "name": "VLP vaccine",
        "platform": "Protein subunit",
        "licenced": "Avian Influenza, HPV, Hep V",
        "pipeline": "process development",
        "capacity": "Yeast cell system - manufacturing - capacity unknown",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1587985200,
        "reference": "http:\/\/artes-biotechnology.biz\/artes-joins-global-combat-against-corona\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Recombinant outer membrane vesicles displaying spike protein",
        "annual_revenue": "7m",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 60,
        "phase0_start": 1587985200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587985200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "60",
        "institutes": "Doherty Institute",
        "country": "Australia",
        "type": "Academic",
        "name": "VLP vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1580212800,
        "reference": "https:\/\/www.doherty.edu.au\/our-work\/institute-themes\/viral-infectious-diseases\/emerging-infections\/2019-novel-coronavirus\/about-2019-novel-coronavirus",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 3,788,774 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 61,
        "phase0_start": 1580212800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1580212800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "61",
        "institutes": "HaloVax\/Hoth Therapeutics",
        "country": "USA",
        "type": "Commercial",
        "name": "Self-assembling vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "Voltron Therapeutics, Inc. and Hoth Therapeutics, Inc.",
        "phase": "Pre-clinical",
        "start_date": 1585310400,
        "reference": "https:\/\/www.biospace.com\/article\/releases\/halovax-announces-agreement-with-hoth-therapeutics-to-joint-develop-a-self-assembling-vaccine-sav-to-protect-patients-at-risk-of-coronavirus-covid-19-infection\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "676,000",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 62,
        "phase0_start": 1585310400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585310400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "62",
        "institutes": "Mahidol University\/GPO",
        "country": "Thailand",
        "type": "Academic",
        "name": "VLP vaccine",
        "platform": "Protein subunit",
        "licenced": "Mitsubishi full vaccine line",
        "pipeline": "Mitsubishi pipeline",
        "capacity": "unknown  ",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1591009200,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "VaxCelerate platform",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 63,
        "phase0_start": 1591009200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "63",
        "institutes": "Medicago Inc\/Mitsubishi \/GSK",
        "country": "Canada",
        "type": "Commercial",
        "name": "Plant-derived VLP vaccine",
        "platform": "Protein subunit",
        "licenced": "Medicago - none\nGSK & Mitsubishi - full vaccine line",
        "pipeline": "Flu, Rotavirus, Norovirus, West Nile virus,\nCancer",
        "capacity": "20 million dose capacity in Quebed plus 20 million dose expansion\n100 million dose capacity in North Carolina plant",
        "alliance": "Mitsubishi vaccines -collaborative agreement with GSK",
        "phase": "Phase I",
        "start_date": 1584014400,
        "reference": "https:\/\/www.biospace.com\/article\/releases\/medicago-announces-production-of-a-viable-vaccine-candidate-for-covid-19\/",
        "phase1_country": "Canada",
        "phase1_start": 1594378800,
        "phase1_end": 1599908400,
        "phase1_trial": "NCT04450004",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Medicago $22.98 M \nMitsubishi $3.83 B\nGSK $33.75 B",
        "committed_doses": " -   ",
        "total_external_funding": " 4,872,446 ",
        "firm_size": "Large Pharma",
        "funding_category": "Large Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 64,
        "phase0_start": 1584014400,
        "phase0_end": 1594378800,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584014400,
            1594378800,
            0,
            0,
            0
        ],
        "end_dates": [
            1594378800,
            1599908400,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 2
    },
    {
        "number": "64",
        "institutes": "Navarrabiomed",
        "country": "Spain",
        "type": "Commercial",
        "name": "VLP vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1591009200,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "can't find looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 65,
        "phase0_start": 1591009200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "65",
        "institutes": "OSIVAX",
        "country": "France",
        "type": "Commercial",
        "name": "VLP vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "Influenza, COVID-19, HPV Malaria",
        "capacity": "None",
        "alliance": "Multiple partnerhips with research institutes and government agencies.  $30 million funding from EIC & BpiFrance",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Lentivirus and baculovirus vehicles\u00a0",
        "annual_revenue": "2.3m",
        "committed_doses": " -   ",
        "total_external_funding": " 19,902,056 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 66,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "66",
        "institutes": "Saiba GmbH",
        "country": "Switzerland",
        "type": "Commercial",
        "name": "VLP vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "VLP vaccine technology",
        "capacity": "AGC biologics - contract manufactruring - capacity unknown but have several other COVID-19 vaccine projects",
        "alliance": "AGC Biologics, other academic institutions",
        "phase": "Pre-clinical",
        "start_date": 1586602800,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "VLP (COVID-19 and SARS1)",
        "annual_revenue": "$465,804 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 67,
        "phase0_start": 1586602800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586602800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "67",
        "institutes": "Ufovax",
        "country": "USA",
        "type": "Commercial",
        "name": "1c-SApNP VLP vaccine\nProtein Nanoparticle vaccines",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "HIV, HCV, RSV, Ebola, Malaria, Tuberculosis, ",
        "capacity": "none",
        "alliance": "Spin-off vaccine company of Scripps Research",
        "phase": "Pre-clinical",
        "start_date": 1586689200,
        "reference": "https:\/\/statnano.com\/news\/67566\/Ufovax-Formulates-COVID-19-Vaccine-Using-its-Nanoparticle-Vaccine-Technology",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "RBD displayed on VLPs",
        "annual_revenue": "can't find looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 68,
        "phase0_start": 1586689200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586689200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "68",
        "institutes": "University of Laval",
        "country": "Canada",
        "type": "Academic",
        "name": "Nanoparticle vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "Medicago - $2.1 million govt of Canada",
        "phase": "Pre-clinical",
        "start_date": 1583496000,
        "reference": "https:\/\/www.ulaval.ca\/en\/about-us\/media-centre\/press-releases\/press-releases-2020\/21-million-better-understand-and-combat-covid-19",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 706,096 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 69,
        "phase0_start": 1583496000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583496000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "69",
        "institutes": "University of Sao Paulo",
        "country": "Brazil",
        "type": "Academic",
        "name": "VLP vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "second generation COVID-19 vaccine",
        "capacity": "none - not expected until 2022",
        "alliance": "Funding from Brazil Govt $1 million to phase I",
        "phase": "Pre-clinical",
        "start_date": 1584532800,
        "reference": "https:\/\/www.efe.com\/efe\/english\/portada\/brazil-scientists-using-new-approach-in-search-for-covid-19-vaccine\/50000260-4199376",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 70,
        "phase0_start": 1584532800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584532800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "70",
        "institutes": "VBI Vaccines\/National Research Council of Canada",
        "country": "Canada\/USA",
        "type": "Commercial\/Academic",
        "name": "VLP vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "HBV, CMV, Corona, GBM, Zika",
        "capacity": "SciVac Development Services, Isreal, capacity unknown",
        "alliance": "National Research Council is an armslength branch of the Canadian Government",
        "phase": "Pre-clinical",
        "start_date": 1585652400,
        "reference": "https:\/\/www.businesswire.com\/news\/home\/20200331005198\/en\/VBI-Vaccines-Announces-Collaboration-National-Research-Council",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$2.2M",
        "committed_doses": " -   ",
        "total_external_funding": " 10,359,259 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 71,
        "phase0_start": 1585652400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585652400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "71",
        "institutes": "AdaptVac",
        "country": "Denmark",
        "type": "Commercial",
        "name": "Capsid-like particle vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "AdaptVac is a joint-venture between NASDAQ First North listed\u00a0ExpreS2ion Biotech\u00a0and University of\u00a0Copenhagen spin-out NextGen Vaccines.\u00a0",
        "phase": "Pre-clinical",
        "start_date": 1583755200,
        "reference": "https:\/\/www.medizin.uni-tuebingen.de\/files\/view\/W0nPpDMa6lLgzbJo9VGLXAbO\/200309%20Press%20release%20Covid-19%20consortium_final.pdf",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Enveloped VLP pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS S proteins",
        "annual_revenue": "can't find looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 72,
        "phase0_start": 1583755200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583755200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "72",
        "institutes": "AJ Vaccines",
        "country": "Denmark",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "pertussis, tetanus, diphtheria, polio, BCG vaccines",
        "pipeline": "unknown  ",
        "capacity": "Copenhagen - former SSI vaccine plant",
        "alliance": "Owned by Aljomaih Group - Saudi Conglomerate",
        "phase": "Pre-clinical",
        "start_date": 1583496000,
        "reference": "https:\/\/ajvaccines.com\/news\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Capsid-like particle",
        "annual_revenue": "$55.57M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 73,
        "phase0_start": 1583496000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583496000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 3
    },
    {
        "number": "73",
        "institutes": "Akers Biosciences\/Premas Biotech ",
        "country": "USA",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "unknown  ",
        "capacity": "none",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1586343600,
        "reference": "https:\/\/www.biospace.com\/article\/releases\/akers-biosciences-and-premas-biotech-announce-successful-expression-of-coronavirus-antigens\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "S protein",
        "annual_revenue": "Akers $1.58M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 74,
        "phase0_start": 1586343600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586343600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "74",
        "institutes": "Anhui Zhifei Longcom Biopharmaceutical\/ Institute of Microbiology, \/Chinese Academy of Sciences",
        "country": "China",
        "type": "Commercial\/Academic",
        "name": "RBD-Dimer vaccine",
        "platform": "Protein subunit",
        "licenced": "Meningococcal and Hib conjugate vaccines",
        "pipeline": "TB, Mening, Pneumo, Shigella, Influenza",
        "capacity": "Yes but details not known",
        "alliance": "Merck",
        "phase": "Phase I\/II",
        "start_date": 1583150400,
        "reference": "http:\/\/hefeihightech.chinadaily.com.cn\/2020-03\/02\/c_459323.htm",
        "phase1_country": "China",
        "phase1_start": 1592823600,
        "phase1_end": 1626865200,
        "phase1_trial": "NCT04445194",
        "phase2_country": "China",
        "phase2_start": 1594551600,
        "phase2_end": 1631703600,
        "phase2_trial": "NCT04466085",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Spike (S), Envelope (E) and Membrane (M) proteins",
        "annual_revenue": "can't find I think probably state funded.",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 75,
        "phase0_start": 1583150400,
        "phase0_end": 1592823600,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583150400,
            1592823600,
            1594551600,
            0,
            0
        ],
        "end_dates": [
            1592823600,
            1626865200,
            1631703600,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "75",
        "institutes": "AnyGo Technology",
        "country": "China",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "None",
        "pipeline": "Veterinary medicines - antibody detection kits",
        "capacity": "none for vaccines",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Adjuvanted recombinant protein (RBD-Dimer)",
        "annual_revenue": "can't find",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 76,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "76",
        "institutes": "Applied Biotechnology Institute Inc",
        "country": "USA",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "Oral Hep B booster vaccine",
        "capacity": "Unknown - through partnerships",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Protein subunit, recombinant S1-Fc fusion protein",
        "annual_revenue": "$550,000 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 77,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "77",
        "institutes": "Axon Neuroscience",
        "country": "Slovakia",
        "type": "Commercial",
        "name": "Peptide vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1586430000,
        "reference": "https:\/\/www.biospace.com\/article\/releases\/axon-neuroscience-has-a-promising-peptide-vaccine-against-covid-19-in-development\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Orally delivered, heat stable subunit",
        "annual_revenue": "$12.17M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 78,
        "phase0_start": 1586430000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586430000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "78",
        "institutes": "Baiya Phytopharm\/Chula VRC",
        "country": "Thailand",
        "type": "Commercial\/Academic",
        "name": "Plant-based vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "HIV, Dengue",
        "capacity": "none",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1591009200,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "can't find looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 79,
        "phase0_start": 1591009200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "79",
        "institutes": "Baylor College of Medicine",
        "country": "USA",
        "type": "Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "Texas Childrens Hospital and Infectious Disease Research Insitute, PATH",
        "phase": "Pre-clinical",
        "start_date": 1584705600,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/novel-coronavirus-landscape-ncov.pdf?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Plant-based subunit; RBD-Fc + Adjuvant",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 1,000,000 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 80,
        "phase0_start": 1584705600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584705600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "80",
        "institutes": "Biological E Ltd",
        "country": "India",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "DPT Hib, MR, Rabies, Hep B, JE, (india & international)",
        "pipeline": "Pneumo Conjugate, Hexavalent, IPV",
        "capacity": "Full scale vaccine manufacturing - March 2021 manufacturing start (process validation batches at full scale)\nCapacity = about 1 bn doses (80 mds \/ mon)\nCritical material supply = adjuvant, vials\nfinal product format = 20 or 45 dose vial",
        "alliance": "not known\nsecured funding = 6.4 million USD",
        "phase": "Pre-clinical",
        "start_date": 1586602800,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "S1 or RBD protein\nAnticipate licence June 2021",
        "annual_revenue": "1088.1 Rs. Crore ~ $147m",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 81,
        "phase0_start": 1586602800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586602800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 3
    },
    {
        "number": "81",
        "institutes": "BiOMVis Srl\/University of Trento",
        "country": "Italy",
        "type": "Commercial\/Academic",
        "name": "OMV-based vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "cancer vaccines",
        "capacity": "none",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1589540400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Adjuvanted protein subunit (RBD)",
        "annual_revenue": "$501,975 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 82,
        "phase0_start": 1589540400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1589540400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "82",
        "institutes": "Boston Children's Hospital",
        "country": "USA",
        "type": "Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1583841600,
        "reference": "https:\/\/discoveries.childrenshospital.org\/coronavirus-vaccine\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "OMV-based vaccine",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 83,
        "phase0_start": 1583841600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583841600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "83",
        "institutes": "Bristish American Tobacco",
        "country": "UK\/USA",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "plant based bioprocessing facility - capacity unknown",
        "alliance": "Kentucky Bioprocessing is a subsidiary",
        "phase": "Pre-clinical",
        "start_date": 1585738800,
        "reference": "https:\/\/www.bat.com\/group\/sites\/UK__9D9KCY.nsf\/vwPagesWebLive\/DOBN8QNL",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "S + adjuvant",
        "annual_revenue": "$25.87 B",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 84,
        "phase0_start": 1585738800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585738800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 3
    },
    {
        "number": "84",
        "institutes": "Chula VRC\/GPO",
        "country": "Thailand",
        "type": "Commercial\/Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "HIV, Dengue",
        "capacity": "none",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1591009200,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Tobacco plant-based vaccine",
        "annual_revenue": "can't find",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 85,
        "phase0_start": 1591009200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "85",
        "institutes": "Clover Biopharmaceuticals Inc\/GSK\/Dynavax",
        "country": "China\/UK\/USA",
        "type": "Commercial",
        "name": "SCB-2019",
        "platform": "Protein subunit",
        "licenced": "None",
        "pipeline": "HIV, RSV, Influenza, Measles, Lassa",
        "capacity": "GSK manufacturing - capacity stated at ",
        "alliance": "GSK, Dynavax",
        "phase": "Phase I",
        "start_date": 1582545600,
        "reference": "https:\/\/www.businesswire.com\/news\/home\/20200224005319\/en",
        "phase1_country": "Australia",
        "phase1_start": 1592650800,
        "phase1_end": 1603191600,
        "phase1_trial": "NCT04405908",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "RBD protein fused with Fc of IgG + Adjuvant",
        "annual_revenue": "GSK $33.75 B Dynavax $35.22M\n",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Large Pharma",
        "funding_category": "Large Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 86,
        "phase0_start": 1582545600,
        "phase0_end": 1592650800,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1582545600,
            1592650800,
            0,
            0,
            0
        ],
        "end_dates": [
            1592650800,
            1603191600,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 2
    },
    {
        "number": "86",
        "institutes": "EpiVax",
        "country": "USA",
        "type": "Commercial",
        "name": "EPV-CoV-19",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "TB, Q fever, Malaria, Smallpox, HIV, Tuleremia, Influenza, H pilori all Pre Clinical",
        "capacity": "None",
        "alliance": "GAIA Vaccine Foundation\n",
        "phase": "Pre-clinical",
        "start_date": 1590577200,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Native-like trimeric subunit spike protein vaccine",
        "annual_revenue": "$3.31 M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 87,
        "phase0_start": 1590577200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1590577200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "87",
        "institutes": "EpiVax\/University of Georgia",
        "country": "USA",
        "type": "Commercial\/Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "TB, Q fever, Malaria, Smallpox, HIV, Tuleremia, Influenza, H pilori all Pre Clinical",
        "capacity": "None",
        "alliance": "https:\/\/epivax.com\/news\/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology",
        "phase": "Pre-clinical",
        "start_date": 1583323200,
        "reference": "https:\/\/epivax.com\/news\/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$3.31 M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 88,
        "phase0_start": 1583323200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583323200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "88",
        "institutes": "ExpreS2ion Biotechnologies",
        "country": "Denmark",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "Malaria vaccines",
        "capacity": "none",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1583496000,
        "reference": "https:\/\/news.cision.com\/expres2ion-biotechnologies\/r\/expres2ion-announces-eu-grant-award-for-the-covid-19-vaccine-development-programme,c3054055",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "S protein",
        "annual_revenue": "$822,133 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 89,
        "phase0_start": 1583496000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583496000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "89",
        "institutes": "Flow Pharma Inc",
        "country": "USA",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine,\nBreastCA vaccine",
        "capacity": "none",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1585224000,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Drosophila S2 insect cell expression system and AdaptVac capsid VLPs",
        "annual_revenue": "can't find looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 90,
        "phase0_start": 1585224000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585224000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "90",
        "institutes": "FSRI SRC VB VECTOR,\/Rospotrebnadzor, Koltsovo\/(protein #1)",
        "country": "Russia",
        "type": "State",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "no data",
        "pipeline": "no data",
        "capacity": "Russia's largest bio manufacturing facility",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "state funded, limited info",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 91,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "91",
        "institutes": "FSRI SRC VB VECTOR,\/Rospotrebnadzor, Koltsovo\/(protein #2)",
        "country": "Russia",
        "type": "State",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "no data",
        "pipeline": "no data",
        "capacity": "Russia's largest bio manufacturing facility",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Peptide vaccine",
        "annual_revenue": "state funded, limited info",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 92,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "92",
        "institutes": "G+Flas Life Sciences",
        "country": "Republic of Korea",
        "type": "Commercial",
        "name": "Plant-based vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1585738800,
        "reference": "http:\/\/www.biospectator.com\/view\/news_view.php?varAtcId=9750",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Subunit vaccine",
        "annual_revenue": "can't find looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 93,
        "phase0_start": 1585738800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585738800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "93",
        "institutes": "Generex\/EpiVax",
        "country": "USA\/Canada",
        "type": "Commercial",
        "name": "Ii-Key peptide vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "TB, Q fever, Malaria, Smallpox, HIV, Tuleremia, Influenza, H pilori all Pre Clinical",
        "capacity": "None",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1582804800,
        "reference": "https:\/\/www.globenewswire.com\/news-release\/2020\/02\/27\/1992098\/0\/en\/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Generex $6.2M \nEpivax $3.31M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 94,
        "phase0_start": 1582804800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1582804800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "94",
        "institutes": "Heat Biologics\/University Of Miami",
        "country": "USA",
        "type": "Commercial\/Academic",
        "name": "gp-96 vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "NSCLC, HIV,\nmalaria, Zika",
        "capacity": "none",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1583409600,
        "reference": "https:\/\/www.heatbio.com\/news-media\/news-releases\/detail\/649\/heat-biologics-announces-research-collaboration-with",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$3.05 M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 95,
        "phase0_start": 1583409600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583409600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "95",
        "institutes": "iBio\/CC-Pharming",
        "country": "USA\/China",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1580731200,
        "reference": "https:\/\/www.globenewswire.com\/news-release\/2020\/02\/03\/1979068\/0\/en\/iBio-and-CC-Pharming-Initiate-Joint-Development-of-Coronavirus-Vaccine.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$2.02 M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 96,
        "phase0_start": 1580731200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1580731200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "96",
        "institutes": "ImmunoPrecise",
        "country": "Canada",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none - Therapeutic antibodies & proteins, ",
        "pipeline": "Therapeutic antibodies & proteins",
        "capacity": "none",
        "alliance": "Lite-Vax (adjuvant), Funded through TRANSVAC 2",
        "phase": "Pre-clinical",
        "start_date": 1582200000,
        "reference": "https:\/\/pipelinereview.com\/index.php\/2020022173854\/Antibodies\/ImmunoPrecise-Launches-Coronavirus-Vaccine-and-Therapeutic-Antibody-Program.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Subunit protein, plant produced",
        "annual_revenue": "$10.93 M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 97,
        "phase0_start": 1582200000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1582200000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "97",
        "institutes": "IMV Inc",
        "country": "USA\/Canada",
        "type": "Commercial",
        "name": "DPX-COVID-19",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "RSV, COVID-19",
        "capacity": "synthetic peptide does not require biological manufacturing",
        "alliance": "The\u00a0Research Centre on Infectious Diseases\u00a0at the University Laval\nhe Canadian Immunization Research Network (CIRN)",
        "phase": "Pre-clinical",
        "start_date": 1585566000,
        "reference": "https:\/\/ir.imv-inc.com\/press-releases\/detail\/638\/imv-inc-provides-updates-on-the-development-of",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$59,000 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 98,
        "phase0_start": 1585566000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585566000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "98",
        "institutes": "InnoMedica",
        "country": "Switzerland",
        "type": "Commercial",
        "name": "TaliCoVax19",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "Chronic diseae vaccines + COVID-19",
        "capacity": "\u00a0The manufacturing unit in Marly is thus able to produce vaccine for up to 150,000 syringes per day.",
        "alliance": "Institute for Virology and Immunology IVI\u00a0in Mittelh\u00e4usern, BE (Switzerland)",
        "phase": "Pre-clinical",
        "start_date": 1587294000,
        "reference": "https:\/\/www.innomedica.com\/en\/2020\/03\/30\/march-2020-innomedica-launches-project-for-corona-vaccination\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Peptide antigens formulated in lipid nanoparticle formulation",
        "annual_revenue": "$329,704 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 99,
        "phase0_start": 1587294000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587294000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "99",
        "institutes": "Innovax\/Xiamen University\/GSK",
        "country": "China\/UK",
        "type": "Commercial\/Academic",
        "name": "COVID-19 XWG-03",
        "platform": "Protein subunit",
        "licenced": "Innovax - HPV, HEV\nGSK - full vaccine line",
        "pipeline": "GSK Pipeline + Dynavax Pipeline",
        "capacity": "not clear - could be GSK or Yangshengtang Group",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1585911600,
        "reference": "https:\/\/www.fiercebiotech.com\/biotech\/gsk-allies-innovax-for-covid-19-vaccine-r-d-project",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "RBD protein expressed from bacteria + liposome carrier system",
        "annual_revenue": "Innovax $863, 655 \nGSK $33.75 B",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Large Pharma",
        "funding_category": "Large Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 100,
        "phase0_start": 1585911600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585911600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 2
    },
    {
        "number": "100",
        "institutes": "Intravacc\/Epivax\u00a0",
        "country": "Netherlands\/USA",
        "type": "Commercial",
        "name": "OMV-peptide\u00a0vaccine",
        "platform": "Protein subunit",
        "licenced": "Co-development vaccine experience",
        "pipeline": "RSV",
        "capacity": "Pilot plant production scale",
        "alliance": "EpiVax",
        "phase": "Pre-clinical",
        "start_date": 1589454000,
        "reference": "https:\/\/www.intravacc.nl\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Truncated S (spike) proteins",
        "annual_revenue": "can't find and 3.31",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 101,
        "phase0_start": 1589454000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1589454000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "101",
        "institutes": "Kentucky Bioprocessing \/(British American Tobacco)",
        "country": "USA",
        "type": "Commercial",
        "name": "RBD-based vaccine",
        "platform": "Protein subunit",
        "licenced": "None",
        "pipeline": "contract manufacturing of proteins and viral vectors",
        "capacity": "Plant based - 3 million plants - 5 week cycle",
        "alliance": "Reynolds Tobacco, British  American Tobacco",
        "phase": "Phase I\/II",
        "start_date": 1585825200,
        "reference": "https:\/\/www.kentucky.com\/news\/coronavirus\/article241709386.html",
        "phase1_country": "TBC",
        "phase1_start": 1595674800,
        "phase1_end": 1607428800,
        "phase1_trial": "NCT04473690",
        "phase2_country": "TBC",
        "phase2_start": 1595674800,
        "phase2_end": 1607428800,
        "phase2_trial": "NCT04473690",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$10.1M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 102,
        "phase0_start": 1585825200,
        "phase0_end": 1595674800,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585825200,
            1595674800,
            1595674800,
            0,
            0
        ],
        "end_dates": [
            1595674800,
            1607428800,
            1607428800,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "102",
        "institutes": "LakePharma Inc",
        "country": "USA",
        "type": "Commercial",
        "name": "Protein subunit, nanoparticle vaccine",
        "platform": "Protein subunit",
        "licenced": "None",
        "pipeline": "contract manufacturing of proteins and viral vectors",
        "capacity": "Full  scale protein manufacturing facility - capacity 100,000,000 doses bulk - finished product somewhat less.\nstarting GMP manufacturing in August 2020. \nstandard CHO process - scale up complete\nfinal product = multidose vials, may be lyophilized",
        "alliance": "unknown  \nno external funding so far",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$29.9M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 103,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "103",
        "institutes": "Liaoning Chengda Biotechnology\/Tsinghua Unverssity",
        "country": "China",
        "type": "Commercial\/Academic",
        "name": "Peptide vaccine",
        "platform": "Protein subunit",
        "licenced": "Rabies, JEV, childhood vaccines",
        "pipeline": "Not known",
        "capacity": "Full scale vacccine manufacturing- 130 million doses\/yr",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1587121200,
        "reference": "https:\/\/www.bioworld.com\/COVID19products",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Nanoparticle vaccine",
        "annual_revenue": "1.29bn Yuan ~ 187m USD",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 104,
        "phase0_start": 1587121200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587121200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 3
    },
    {
        "number": "104",
        "institutes": "Lomonosov Moscow State University\u00a0",
        "country": "Russia",
        "type": "Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1588330800,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 105,
        "phase0_start": 1588330800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588330800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "105",
        "institutes": "Max Planck Institute of\/Colloids and Interfaces (subunit)",
        "country": "Germany",
        "type": "Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1589367600,
        "reference": "https:\/\/www.mpg.de\/14807464\/0511-mpin-116799-corona-vaccination-via-the-skin",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Structurally modified spherical particles of the tobacco mosaic virus (TMV)\u00a0",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 106,
        "phase0_start": 1589367600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1589367600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "106",
        "institutes": "Medigen Vaccine Biologics Corp\/NAID\/Dynavax",
        "country": "Taiwan\/USA",
        "type": "Commercial\/Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "No details on licensed products",
        "pipeline": "EV71, Influenza, Dengue",
        "capacity": "Manufacturing facillity - capacity unknown",
        "alliance": "NAID, Dynavax, Utrecht Centre for Affordable Biotherapeutics for Public Health, NIH,CDC",
        "phase": "Phase I",
        "start_date": 1581940800,
        "reference": "https:\/\/www.pharmashots.com\/press-releases\/taiwan-firm-teams-up-with-us-to-develop-covid-19-vaccine\/",
        "phase1_country": "Taiwan",
        "phase1_start": 1598958000,
        "phase1_end": 1640952000,
        "phase1_trial": "NCT04487210",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "S protein plus targeting ligand for Langerhans cells",
        "annual_revenue": "v. small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 107,
        "phase0_start": 1581940800,
        "phase0_end": 1598958000,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1581940800,
            1598958000,
            0,
            0,
            0
        ],
        "end_dates": [
            1598958000,
            1640952000,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "107",
        "institutes": "MOGAM Institute for Biomedical Research\/ GC Pharma",
        "country": "Republic of Korea",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "Tetanus, Diphtheria, influenza",
        "pipeline": "DPT, Tuberculosis, Varicella",
        "capacity": "IDRI will provide manufacturing",
        "alliance": "Owns Curevo Vaccine company and linked to IDIR and MIBR",
        "phase": "Pre-clinical",
        "start_date": 1584619200,
        "reference": "http:\/\/www.businesskorea.co.kr\/news\/articleView.html?idxno=42991",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "S-2 P protein + CpG 1018",
        "annual_revenue": "KRW 1,369.7 billion ~1.16bn USD",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 108,
        "phase0_start": 1584619200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584619200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 3
    },
    {
        "number": "108",
        "institutes": "National Institute of Infectious Disease",
        "country": "Japan",
        "type": "Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "Infleunza, Measles, Covid-19",
        "capacity": "unknown ",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1586602800,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Synthetic antigen-based ubunit vaccine",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 109,
        "phase0_start": 1586602800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586602800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "109",
        "institutes": "Neovii\/Tel Aviv University",
        "country": "Israel",
        "type": "Commercial\/Academic",
        "name": "RBD-based vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "Neovii will develop and manufacture the Tel Aviv University patent COVID-19 construct",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1589367600,
        "reference": "https:\/\/neovii.com\/neovii-partners-with-tel-aviv-university-to-develop-novel-covid-19-vaccine\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "S protein + adjuvant",
        "annual_revenue": "$1.84M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 110,
        "phase0_start": 1589367600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1589367600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "110",
        "institutes": "Novavax",
        "country": "USA",
        "type": "Commercial",
        "name": "NVX-CoV2373",
        "platform": "Protein subunit",
        "licenced": "None",
        "pipeline": "RSV, Ebola, Influenza Phase 1 to 3",
        "capacity": "Agc Biologics, Novavax acquires  Praha Vaccines Czech Rep - 1 billion doses starting 2021\nFUJUFILM diosynth Biotechnologies begin large scale manufacturing",
        "alliance": "AGC Biologics, Cyrus Poonawalla Group India (Serum Institute of India)",
        "phase": "Phase I",
        "start_date": 1583841600,
        "reference": "https:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-awarded-funding-cepi-covid-19-vaccine-development",
        "phase1_country": "Australia",
        "phase1_start": 1590404400,
        "phase1_end": 1609416000,
        "phase1_trial": "NCT04368988",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "RBD-based\u00a0",
        "annual_revenue": "$18.66 M",
        "committed_doses": " 160,000,000 ",
        "total_external_funding": " 484,952,384 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Large external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 111,
        "phase0_start": 1583841600,
        "phase0_end": 1590404400,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583841600,
            1590404400,
            0,
            0,
            0
        ],
        "end_dates": [
            1590404400,
            1609416000,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 0
    },
    {
        "number": "111",
        "institutes": "OncoGen",
        "country": "Romania",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1585224000,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "VLP-recombinant protein nanoparticle vaccine + Matrix M",
        "annual_revenue": "$75,000 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 112,
        "phase0_start": 1585224000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585224000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "112",
        "institutes": "Osaka University\/BIKEN\/NIBIOHN (subunit)",
        "country": "Japan",
        "type": "Commercial\/Academic",
        "name": "VLP-recombinant protein vaccine",
        "platform": "Protein subunit",
        "licenced": "Biken - Var, MR, Flu, DPT & Polio",
        "pipeline": "not known",
        "capacity": "Biken has manufacturing - unknown capacity",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1586602800,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Synthetic long peptide vaccine candidate for S and M proteins",
        "annual_revenue": "BIKEN $333.20M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 113,
        "phase0_start": 1586602800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586602800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 3
    },
    {
        "number": "113",
        "institutes": "PDS Biotechnology",
        "country": "USA",
        "type": "Commercial",
        "name": "PDS0203, PDS0204",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "preclinical influenza, TB, COVID-19",
        "capacity": "none",
        "alliance": "Farmacore, Brazilian govt funding",
        "phase": "Pre-clinical",
        "start_date": 1587034800,
        "reference": "https:\/\/www.globenewswire.com\/news-release\/2020\/04\/16\/2017301\/0\/en\/PDS-Biotechnology-Initiates-Novel-Vaccine-Development-Programs-For-COVID-19-and-Universal-Influenza-Delay-of-PDS0101-VERSATILE-002-trial.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "VLP-recombinant protein + adjuvant",
        "annual_revenue": "$98,414 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 114,
        "phase0_start": 1587034800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587034800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "114",
        "institutes": "Quadram Institute Biosciences",
        "country": "UK",
        "type": "Commercial\/Academic",
        "name": "OMV-based vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "WHO expert group",
        "phase": "Pre-clinical",
        "start_date": 1588849200,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Versamune T-cell activating technology with Sars-CoV-2 antigens",
        "annual_revenue": "15.8 m GBP",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 115,
        "phase0_start": 1588849200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588849200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "115",
        "institutes": "Sanofi Pasteur\/ GSK",
        "country": "France",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "DPT, Polio, Hib, Meningococcal, Influenza, Typhoid, Hep A, BCG, etc",
        "pipeline": "HSV, RSV, Pneumo conj, HIV, ",
        "capacity": "four manufacturing facilities globally",
        "alliance": "Collaboration with GSK adjuvant",
        "phase": "Pre-clinical",
        "start_date": 1584705600,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Bacterial extracellular vesicle (BEV)-based mucosal vaccine.\u00a0",
        "annual_revenue": "$42.147 B",
        "committed_doses": " 460,000,000 ",
        "total_external_funding": " 1,080,775,336 ",
        "firm_size": "large pharma",
        "funding_category": "Large external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 116,
        "phase0_start": 1584705600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584705600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 0
    },
    {
        "number": "116",
        "institutes": "Shionogi",
        "country": "Japan",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "influenza",
        "capacity": "not known",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1588071600,
        "reference": "https:\/\/www.businesswire.com\/news\/home\/20200428005509\/en\/Shionogi-Accelerates-Development-Potential-COVID-19-Treatments-Vaccine",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "S protein (baculovirus production)",
        "annual_revenue": "333.37B JPY ~3.16B USD",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 117,
        "phase0_start": 1588071600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588071600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 3
    },
    {
        "number": "117",
        "institutes": "Sichuan University\/Zhejiang Teruisi Pharmaceutical\/Others",
        "country": "China",
        "type": "Commercial\/Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "no information in english",
        "pipeline": "no information in english",
        "capacity": "no information in english",
        "alliance": "no information in english",
        "phase": "Pre-clinical",
        "start_date": 1587121200,
        "reference": "https:\/\/www.biocentury.com\/article\/304515",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Recombinant protein using baculovirus expression vector",
        "annual_revenue": "10.72bn CNY ~ 1.56USD",
        "committed_doses": " -   ",
        "total_external_funding": " 69,500,000 ",
        "firm_size": "Medium Pharma",
        "funding_category": "Some external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 118,
        "phase0_start": 1587121200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587121200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 1
    },
    {
        "number": "118",
        "institutes": "SK Biosciences",
        "country": "Republic of Korea",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "Influenza, Zoster, Varicella",
        "pipeline": "influenza, rotavirus, rabies, dengue, polio, JEV, EV71, yellow fever, 13valent PCV and RSV vaccine",
        "capacity": "L HOUSE, located in Andong Gyeongbuk Bio Industrial Complex",
        "alliance": "Sanofi Pasteur, Gates Foundation funding $3.6 million, Govt of Korea",
        "phase": "Pre-clinical",
        "start_date": 1584964800,
        "reference": "http:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=7798",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Much of their revenue is non-pharma. I think Mediam but its hard to be sure",
        "committed_doses": " -   ",
        "total_external_funding": " 3,600,000 ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 119,
        "phase0_start": 1584964800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584964800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 3
    },
    {
        "number": "119",
        "institutes": "St Petersburg Scientific Research Institute \/of Vaccines and Sera",
        "country": "Russia",
        "type": "Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "no information in english",
        "pipeline": "no information in english",
        "capacity": "no information in english",
        "alliance": "State Research Institute, State funding, ",
        "phase": "Pre-clinical",
        "start_date": 1586602800,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 120,
        "phase0_start": 1586602800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586602800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "120",
        "institutes": "University of Alberta",
        "country": "Canada",
        "type": "Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "Hep C",
        "capacity": "Alberta Cell Therapy Manufacturing Facility , UofA, Edmonton Capacity unknown",
        "alliance": "Canadian Govt funding $750K, CIHR, ",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Recombinant protein, nanoparticles (based on S-protein and other epitopes)",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 1,962,550 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 121,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "121",
        "institutes": "University of California, San Diego",
        "country": "USA",
        "type": "Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "unknown - looks to be a challenge",
        "alliance": "none identified",
        "phase": "Pre-clinical",
        "start_date": 1587380400,
        "reference": "https:\/\/ucsdnews.ucsd.edu\/pressrelease\/marrying-molecular-farming-and-advanced-manufacturing-to-develop-a-covid-19-vaccine",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Spike based",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 122,
        "phase0_start": 1587380400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587380400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "122",
        "institutes": "University of Pittsburgh",
        "country": "USA",
        "type": "Academic",
        "name": "PittCoVacc",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "small scale cell factory,  no commercial scale manufacturing identified",
        "alliance": "HIAIH",
        "phase": "Pre-clinical",
        "start_date": 1585825200,
        "reference": "https:\/\/www.upmc.com\/media\/news\/040220-falo-gambotto-sars-cov2-vaccine",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 123,
        "phase0_start": 1585825200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585825200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "123",
        "institutes": "University of Queensland\/GSK\/Dynavax",
        "country": "Australia\/UK",
        "type": "Commercial\/Academic",
        "name": "Molecular clamp vaccine",
        "platform": "Protein subunit",
        "licenced": "GSK - full line of vaccines\nDynavax - Hep B",
        "pipeline": "GSK Pipeline + Dynavax Pipeline",
        "capacity": "Production:  CSL\u2019s Australian facilities will produce several million antigen doses by the end of this year.  A portion of these will be used in Phase II\/III clinical studies with the remainder available as soon as marketing authorisation is granted. Further scale-up of production will be achieved in partnership with a contract manufacturer, supplying up to 100 million doses during 2021. \nCSL subsidiary, CSL Behring, has the existing capability in Victoria to manufacture enough doses of a COVID-19 vaccine to service Australia\u2019s population.\nproduct format = multidose vials",
        "alliance": "CSL, CEPI\n\u2022 As part of the arrangement, CSL has contributed technical expertise to UQ\u2019s pre-clinical activities and phase 1 clinical study, as well as provision of Seqirus\u2019 adjuvant MF59.  CSL will take on full responsibility for subsequent clinical studies as the manufacturer of UQ\u2019s candidate COVID-19 vaccine.\nCSL is confident that the production technology can be scaled to up to tens of millions of doses by 2021 \n\u2022 CSL has the rights to undertake full scale manufacture of the vaccine, including the ability to partner with other contract manufacturing organisations (CMOs) to produce volumes to support global requirements.\nCSL and CEPI will equally share the allocation of the doses ",
        "phase": "Phase I",
        "start_date": 1579867200,
        "reference": "https:\/\/www.uq.edu.au\/news\/article\/2020\/01\/race-develop-coronavirus-vaccine",
        "phase1_country": "Australia",
        "phase1_start": 1594724400,
        "phase1_end": 0,
        "phase1_trial": "ACTRN12620000674932",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Microneedle arrays S1 subunit\nexpect license in 2021",
        "annual_revenue": "GSK is big pharma\n",
        "committed_doses": " -   ",
        "total_external_funding": " 21,775,656 ",
        "firm_size": "Large Pharma",
        "funding_category": "Large Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 124,
        "phase0_start": 1579867200,
        "phase0_end": 1594724400,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1579867200,
            1594724400,
            0,
            0,
            0
        ],
        "end_dates": [
            1594724400,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 2
    },
    {
        "number": "124",
        "institutes": "University of San Martin\/& CONICET",
        "country": "Argentina",
        "type": "Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "national Scientific and Technical Research Council",
        "phase": "Pre-clinical",
        "start_date": 1591959600,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Molecular clamp stabilized spike protein",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 125,
        "phase0_start": 1591959600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591959600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "125",
        "institutes": "Vabiotech",
        "country": "Vietnam",
        "type": "State\/Commercial",
        "name": "IC-BEVS",
        "platform": "Protein subunit",
        "licenced": " JEV, Cholora, HepB, HepA, ",
        "pipeline": "Plasmid Vaccines",
        "capacity": "Yes - capacity unknown",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "state compnay",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 126,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "126",
        "institutes": "Vaxil Bio",
        "country": "Israel",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "TB pre-clinical",
        "capacity": "none",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1581595200,
        "reference": "https:\/\/pipelinereview.com\/index.php\/2020021673805\/Vaccines\/Vaxil-Announces-the-Identification-of-a-Potential-Corona-Virus-Vaccine-and-Provides-an-Update-in-the-Previously-Announced-Debt-Financing.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Protein subunit, recombinant S protein in IC-BEVS  ",
        "annual_revenue": "$100,000 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 127,
        "phase0_start": 1581595200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1581595200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "127",
        "institutes": "Vaxine Pty\/Flinders University\/Oracle",
        "country": "Australia",
        "type": "Commercial\/Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "Influenza",
        "pipeline": "RSV, JE, Ebola TB, HIV & others",
        "capacity": "Vaxine Pty - capacity not known",
        "alliance": "none identified",
        "phase": "Phase I",
        "start_date": 1585911600,
        "reference": "https:\/\/news.flinders.edu.au\/blog\/2020\/04\/03\/flinders-targets-covid-19-vaccine\/",
        "phase1_country": "Australia",
        "phase1_start": 1593514800,
        "phase1_end": 1625137200,
        "phase1_trial": "NCT04453852",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "8 M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 128,
        "phase0_start": 1585911600,
        "phase0_end": 1593514800,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585911600,
            1593514800,
            0,
            0,
            0
        ],
        "end_dates": [
            1593514800,
            1625137200,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "128",
        "institutes": "Versatope\/Umass (subunit)",
        "country": "USA",
        "type": "Commercial\/Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none (immune therapeutic company)",
        "pipeline": "Influenza ",
        "capacity": "none",
        "alliance": "seeking NIIH and public\/private funding",
        "phase": "Pre-clinical",
        "start_date": 1585566000,
        "reference": "https:\/\/www.uml.edu\/News\/stories\/2020\/M2D2-coronavirus-efforts.aspx?mc_cid=b01e8bd49c&mc_eid=565cb5181a",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Recombinant spike protein with Advax\u2122 adjuvant",
        "annual_revenue": "$92,591 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 129,
        "phase0_start": 1585566000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585566000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "129",
        "institutes": "VIDO-InterVac\/ University of Saskatchewan",
        "country": "Canada",
        "type": "Academic",
        "name": "Adjuvanted microsphere peptide",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "    Chlamydia, Salmonella, Gonorrhea, influneza, MERS Parainflluenza, RSV, TB, Pertrusis, Zika",
        "capacity": "level 2 and level 3 containment, intermediate scale manufacturing, \nlarger scale manufacturing in development - completion within 1 year - 30 to 60 million dose capacity  \nGMP manufacturing of the components of the vaccine have already been initiated\nScale up still in progress - the process at scale is not finalized.\nPartnership with Dalton for formulation fill & pack",
        "alliance": "U Saskatchewan, Canadain Government $40 million\nadditional operational funds to facilitate the ongoing research in containment level 3 (CL3)\nPartnership with Dalton (CMO)",
        "phase": "Pre-clinical",
        "start_date": 1584705600,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/novel-coronavirus-landscape-ncov.pdf?ua=1",
        "phase1_country": " ",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Polypeptide-based",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 32,942,670 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 130,
        "phase0_start": 1584705600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584705600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "130",
        "institutes": "Walter Reed Army Institute of Research\/USAMRIID",
        "country": "USA",
        "type": "Academic",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "long history of vaccine development for military application",
        "capacity": "none",
        "alliance": "US Government funding",
        "phase": "Pre-clinical",
        "start_date": 1583409600,
        "reference": "https:\/\/www.defense.gov\/Newsroom\/Transcripts\/Transcript\/Article\/2104736\/defense-department-press-briefing-investigating-and-developing-vaccine-candidat\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " - ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Large external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 131,
        "phase0_start": 1583409600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583409600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 0
    },
    {
        "number": "131",
        "institutes": "Yisheng Biopharma",
        "country": "China",
        "type": "Commercial",
        "name": "Protein subunit vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "Mainly Cancer therapies but also two vaccines - Rabies, HBV",
        "capacity": "none",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "S protein",
        "annual_revenue": "$694,536 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 132,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "178",
        "institutes": "Helix Biogen Consult\/Elizade University\/Massasoit Community College\/Ladoke Akintola University ",
        "country": "Nigeria ",
        "type": "Commercial\/Academic",
        "name": "Unnamed vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1591009200,
        "reference": "https:\/\/www.pulse.ng\/news\/local\/covid-19-nigerian-scientists-working-on-preventive-vaccines-call-for-assistance\/x256s7z",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "exoVACC exome platform",
        "annual_revenue": "it\u2019s a consultinancy and 4 universities ",
        "committed_doses": " -   ",
        "total_external_funding": " 20,129 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 133,
        "phase0_start": 1591009200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "181",
        "institutes": "MIGAL Galilee Research Institute",
        "country": "Israel",
        "type": "Academic",
        "name": "Modified avian coronavirus vaccine",
        "platform": "Protein subunit",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1582804800,
        "reference": "http:\/\/www.migal.org.il\/Migal.covid",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 134,
        "phase0_start": 1582804800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1582804800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "228",
        "institutes": "Research Institute for\/ Biological Safety Problems",
        "country": "Republic of Kazakhstan",
        "type": "Academic",
        "name": "",
        "platform": "Protein subunit",
        "licenced": "unknown  ",
        "pipeline": "unknown  ",
        "capacity": "unknown  ",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1589540400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 135,
        "phase0_start": 1589540400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1589540400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 4
    },
    {
        "number": "229",
        "institutes": "Shionogi",
        "country": "Japan",
        "type": "commercial",
        "name": "Baculovirus Expression Vector System",
        "platform": "Protein subunit",
        "licenced": "none\nsmall molecule pharma",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "30 million people by the end of 2021 through UNIGEN Inc.",
        "phase": "Pre-clinical",
        "start_date": 0,
        "reference": "https:\/\/www.shionogi.com\/global\/en\/news\/2020\/08\/e-200807_2.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "333.37B JPY ~3.16B USD",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 136,
        "phase0_start": 0,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 1,
        "funding_key": 3
    },
    {
        "number": "26",
        "institutes": "DZIF - German Center for Infection\/Research (live)",
        "country": "Germany",
        "type": "Academic",
        "name": "Replicating Vector",
        "platform": "Replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "multiple institutions",
        "phase": "Pre-clinical",
        "start_date": 1585224000,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Measles virus (S, N targets)",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 137,
        "phase0_start": 1585224000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585224000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "132",
        "institutes": "BIOCAD\/IEM",
        "country": "Russia",
        "type": "Commercial",
        "name": "Replicating viral vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "none - mainly biological therapeutics",
        "pipeline": "none - mainly biolobical thereapeutics - oncology, autoimmune, cardiology",
        "capacity": "Yes but no details wrt vaccines",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1586602800,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Hard to get exact figures but seems very much to be medium",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 138,
        "phase0_start": 1586602800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586602800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 3
    },
    {
        "number": "133",
        "institutes": "FluGen\/Bharat Biotech\/UW-Madison",
        "country": "USA\/India",
        "type": "Commercial\/Academic",
        "name": "CoroFlu",
        "platform": "Replicating viral vector",
        "licenced": "Hib, DPT combinations, Rabies JEV, Rota, HepB",
        "pipeline": "Zika,Chikungunya, HPV, pertussis, malaria, polio, paratyphoid",
        "capacity": "largest manufacturing facility in Asia\/Pacific region - 300 million doses\/rear",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1585825200,
        "reference": "https:\/\/www.pharmaceutical-technology.com\/news\/flugen-bharat-bio-uw-madison-covid-vaccine\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)",
        "annual_revenue": "1.2m, 6.7m and accademic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 139,
        "phase0_start": 1585825200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585825200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "134",
        "institutes": "FSRI SRC VB VECTOR,\/Rospotrebnadzor, Koltsovo\/(vector #1)",
        "country": "Russia",
        "type": "State",
        "name": "Replicating viral vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "no information",
        "pipeline": "no information",
        "capacity": "no information",
        "alliance": "no information",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "M2SR platform; self-limiting replication; intranasal",
        "annual_revenue": "State",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 140,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "135",
        "institutes": "FSRI SRC VB VECTOR,\/Rospotrebnadzor, Koltsovo\/(vector #2)",
        "country": "Russia",
        "type": "State",
        "name": "Replicating viral vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "no information",
        "pipeline": "no information",
        "capacity": "no information",
        "alliance": "no information",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Measles Vector",
        "annual_revenue": "State",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 141,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "136",
        "institutes": "FSRI SRC VB VECTOR,\/Rospotrebnadzor, Koltsovo\/(vector #3)",
        "country": "Russia",
        "type": "State",
        "name": "Replicating viral vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "no information",
        "pipeline": "no information",
        "capacity": "no information",
        "alliance": "no information",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Recombinant vaccine based on Influenza A virus, intranasal vaccine",
        "annual_revenue": "State",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 142,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "137",
        "institutes": "Funda\u00e7\u00e3o Oswaldo Cruz (FIOCRUZ)\/Instituto Buntantan",
        "country": "Brazil",
        "type": "Academic",
        "name": "Replicating viral vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "DPT combinations, HepB, BCG, Rabies, Polio, Hib, YF, MMR, ",
        "pipeline": "unknown",
        "capacity": "250 milion dose capacity",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1588330800,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Replicating viral vector; VSV vector",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 143,
        "phase0_start": 1588330800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588330800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "138",
        "institutes": "IAVI\/Merck",
        "country": "USA",
        "type": "Commercial\/Academic",
        "name": "VSV vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "HIV MMR Varicella, Zoster, HPV Hep A Hep B, ebola, pneumococcal, rota, hib, ",
        "pipeline": "RSV, CMV, Pneumoconjugate, ",
        "capacity": "Yes - capacity unknown",
        "alliance": "Unknown",
        "phase": "Phase I",
        "start_date": 1583409600,
        "reference": "https:\/\/www.iavi.org\/newsroom\/press-releases\/2020\/iavi-and-batavia-announce-collaboration-vsv-vector-epidemic-preparedness-vaccines",
        "phase1_country": "TBC",
        "phase1_start": 1597834800,
        "phase1_end": 1647432000,
        "phase1_trial": "NCT04498247",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Attenuated Influenza expressing an antigenic portion of the Spike protein",
        "annual_revenue": "$46.59B",
        "committed_doses": " -   ",
        "total_external_funding": " 38,033,570 ",
        "firm_size": "Large Pharma",
        "funding_category": "Large Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 144,
        "phase0_start": 1583409600,
        "phase0_end": 1597834800,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583409600,
            1597834800,
            0,
            0,
            0
        ],
        "end_dates": [
            1597834800,
            1647432000,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 2
    },
    {
        "number": "139",
        "institutes": "Institut Pasteur\/Themis\/University of Pittsburg\/Merck",
        "country": "France\/USA\/Austria",
        "type": "Commercial\/Academic",
        "name": "Replicating viral vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "HIV MMR Varicella, Zoster, HPV Hep A Hep B, ebola, pneumococcal, rota, hib, ",
        "pipeline": "lasa, MERS, CMV, RSV, Noro, Zika, Chikungunya",
        "capacity": "Yes - capacity unknown",
        "alliance": "Unknown",
        "phase": "Pre-clinical",
        "start_date": 1584619200,
        "reference": "https:\/\/www.themisbio.com\/cepi-collaborates-with-the-institut-pasteur-in-a-consortium-to-develop-covid-19-vaccine\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "VSV vector expressing RBD",
        "annual_revenue": "$46.59B",
        "committed_doses": " -   ",
        "total_external_funding": " 7,077,819 ",
        "firm_size": "Large Pharma",
        "funding_category": "Large Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 145,
        "phase0_start": 1584619200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584619200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 2
    },
    {
        "number": "140",
        "institutes": "Intravacc\/Wageningen Bioveterinary Research\/Utrecht University",
        "country": "Netherlands\/Germany",
        "type": "Commercial\/Academic",
        "name": "NDV-SARS-CoV-2\/Spike\u00a0",
        "platform": "Replicating viral vector",
        "licenced": "Polio",
        "pipeline": "OPV HPV RSV Measles, Rabies, Rota",
        "capacity": "yes - vero cell platform - capacity unknown",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1589454000,
        "reference": "https:\/\/www.intravacc.nl\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Measles Vector",
        "annual_revenue": "can't find inravacc details, Wagening is \u20ac367m",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 146,
        "phase0_start": 1589454000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1589454000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 3
    },
    {
        "number": "141",
        "institutes": "KU Leuven",
        "country": "Belgium",
        "type": "Academic",
        "name": "YF17D vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1580126400,
        "reference": "https:\/\/www.brusselstimes.com\/all-news\/belgium-all-news\/92085\/ku-leuven-researchers-near-test-phase-for-coronavirus-vaccine-wuhan-china-infection-virus-france\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 147,
        "phase0_start": 1580126400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1580126400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "142",
        "institutes": "Lancaster University",
        "country": "UK",
        "type": "Academic",
        "name": "APM vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "none",
        "phase": "Pre-clinical",
        "start_date": 1589540400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Yellow fever vaccine backbone with SARS-CoV-2 spike protein",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 148,
        "phase0_start": 1589540400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1589540400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "143",
        "institutes": "Sumagen\/International Vaccine Institute",
        "country": "Republic of Korea",
        "type": "Commercial\/Academic",
        "name": "VSV vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "none",
        "pipeline": "HIV",
        "capacity": "IVI partnership with asian pacific manufacturers - details and capacity unknown",
        "alliance": "IVI funding ",
        "phase": "Pre-clinical",
        "start_date": 1583496000,
        "reference": "https:\/\/pulsenews.co.kr\/view.php?year=2020&no=237416",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Avian paramyxovirus vector (APMV)\u00a0",
        "annual_revenue": "3.7m and accademic",
        "committed_doses": " -   ",
        "total_external_funding": " 1,085,788 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 149,
        "phase0_start": 1583496000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583496000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "144",
        "institutes": "Tonix Pharma\/Southern Research",
        "country": "USA",
        "type": "Commercial",
        "name": "Horsepox vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "biodefence vaccines - smallpox",
        "pipeline": "smallpox",
        "capacity": "yes - capacity not known",
        "alliance": "SR not for profit collaborative research oganization",
        "phase": "Pre-clinical",
        "start_date": 1585051200,
        "reference": "https:\/\/ir.tonixpharma.com\/press-releases\/detail\/1195\/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "VSV vector",
        "annual_revenue": "$26,000 ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 150,
        "phase0_start": 1585051200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585051200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "145",
        "institutes": "University of Hong Kong",
        "country": "Hong Kong",
        "type": "Academic",
        "name": "Replicating viral vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "none",
        "pipeline": "MERS",
        "capacity": "Evaluating production partnerships with Xiamen University, Changchun-Baike, Hualan-Bio, Beijing Wantai, Sinovac, and CNBG China - capacity unknown",
        "alliance": "CEPI - $620,000",
        "phase": "Phase I\/II\/III",
        "start_date": 1585224000,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_Mar26.PDF",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Horsepox vector expressing S protein",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 620,000 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 151,
        "phase0_start": 1585224000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585224000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "146",
        "institutes": "University of Western Ontario",
        "country": "Canada",
        "type": "Academic",
        "name": "VSV-S",
        "platform": "Replicating viral vector",
        "licenced": "none",
        "pipeline": "MERS",
        "capacity": "none",
        "alliance": "CIHR - $1 million",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Influenza vector expressing RBD",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 705,732 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 152,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 4
    },
    {
        "number": "147",
        "institutes": "Zydus Cadila (vector vaccine)",
        "country": "India",
        "type": "Commercial",
        "name": "Replicating viral vector vaccine",
        "platform": "Replicating viral vector",
        "licenced": "Influenza, typhoid",
        "pipeline": "Human Papilloma Virus, Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola and Japanese Encephalitis.",
        "capacity": "Yes - capacity unknown",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1584705600,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/novel-coronavirus-landscape-ncov.pdf?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Replicating viral vector; VSV-S",
        "annual_revenue": "$1.9B",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 153,
        "phase0_start": 1584705600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584705600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 3
    },
    {
        "number": "222",
        "institutes": "Merck",
        "country": "USA",
        "type": "Commercial",
        "name": "V519",
        "platform": "Replicating viral vector",
        "licenced": "HIV MMR Varicella, Zoster, HPV Hep A Hep B, ebola, pneumococcal, rota, hib, ",
        "pipeline": "RSV, CMV, Pneumoconjugate, ",
        "capacity": "Yes - capacity unknown",
        "alliance": "recent buyout of Themis",
        "phase": "Pre-clinical",
        "start_date": 1589972400,
        "reference": "https:\/\/www.fiercebiotech.com\/biotech\/merck-via-its-themis-buy-to-move-first-covid-19-vaccine-into-clinical-development-q3",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$46.59B",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Large Pharma",
        "funding_category": "Large Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 154,
        "phase0_start": 1589972400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1589972400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 5,
        "funding_key": 2
    },
    {
        "number": "148",
        "institutes": "Arcturus\/Duke-NUS",
        "country": "USA\/Singapore",
        "type": "Commercial\/Academic",
        "name": "LUNAR-COV19",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "",
        "phase": "Phase I\/II",
        "start_date": 1583323200,
        "reference": "https:\/\/ir.arcturusrx.com\/news-releases\/news-release-details\/arcturus-therapeutics-and-duke-nus-medical-school-partner",
        "phase1_country": "Singapore",
        "phase1_start": 1593601200,
        "phase1_end": 1609416000,
        "phase1_trial": "NCT04480957",
        "phase2_country": "Singapore",
        "phase2_start": 1593601200,
        "phase2_end": 1609416000,
        "phase2_trial": "NCT04480957",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Measles vector",
        "annual_revenue": "$20.8M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 155,
        "phase0_start": 1583323200,
        "phase0_end": 1593601200,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583323200,
            1593601200,
            1593601200,
            0,
            0
        ],
        "end_dates": [
            1593601200,
            1609416000,
            1609416000,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "149",
        "institutes": "BIOCAD",
        "country": "Russia",
        "type": "Commercial",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "none - mainly biological therapeutics",
        "pipeline": "none - mainly biolobical thereapeutics - oncology, autoimmune, cardiology",
        "capacity": "Yes but no details wrt vaccines",
        "alliance": "not known",
        "phase": "Pre-clinical",
        "start_date": 1584619200,
        "reference": "https:\/\/biocadglobal.com\/index.php?posts&post=45",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Hard to get exact figures but seems very much to be medium",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 156,
        "phase0_start": 1584619200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584619200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 3
    },
    {
        "number": "150",
        "institutes": "BioNTech\/Fosun Pharma\/Pfizer",
        "country": "Germany\/USA",
        "type": "Commercial",
        "name": "BNT162",
        "platform": "RNA",
        "licenced": "Ebola\n\nPfizer full range of vaccines",
        "pipeline": "meningitis, pneumonia, tuberculosis, COVID-19,\u00a0Ebola virus disease, pertussis, diphtheria, tetanus, shingles",
        "capacity": "pilot plant + commercial manufacturing 70 million to 80 million doses cGMP approved FDA, EU, WHO and China",
        "alliance": "unknown  ",
        "phase": "Phase I\/II\/III",
        "start_date": 1584446400,
        "reference": "https:\/\/www.businesswire.com\/news\/home\/20200316005943\/en\/",
        "phase1_country": "Germany\/USA\n\nGermany\nChina\nChina",
        "phase1_start": 1588158000,
        "phase1_end": 1628679600,
        "phase1_trial": "NCT04368728\/ EudraCT2020-001038-36\nNCT04380701\nChiCTR2000034825\nNCT04523571",
        "phase2_country": "Germany",
        "phase2_start": 1587639600,
        "phase2_end": 1598871600,
        "phase2_trial": "NCT04380701",
        "phase3_country": "USA",
        "phase3_start": 1588158000,
        "phase3_end": 1624878000,
        "phase3_trial": "NCT04368728",
        "other": "",
        "annual_revenue": "BioNTech $108M \nFosun Pharma $16.5B\nPfizer $49.197 B\n",
        "committed_doses": " 230,000,000 ",
        "total_external_funding": " -   ",
        "firm_size": "large pharma",
        "funding_category": "Large external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 157,
        "phase0_start": 1584446400,
        "phase0_end": 1588158000,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584446400,
            1588158000,
            1587639600,
            1588158000,
            0
        ],
        "end_dates": [
            1588158000,
            1628679600,
            1598871600,
            1624878000,
            0
        ],
        "platform_key": 3,
        "funding_key": 0
    },
    {
        "number": "151",
        "institutes": "China CDC\/Tongji University\/Stermina Therapeutics",
        "country": "China",
        "type": "Commercial\/Academic",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "TB, HPV, Influenza, Ebola",
        "capacity": "",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1584446400,
        "reference": "https:\/\/news.cgtn.com\/news\/2020-03-17\/Shanghai-announces-steady-progress-in-COVID-19-vaccine-development--OVydZfNUFG\/index.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "can't find ",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 158,
        "phase0_start": 1584446400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584446400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "152",
        "institutes": "Chula VRC\/University of Pennsylvania",
        "country": "Thailand\/USA",
        "type": "Academic",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "HIV, Dengue",
        "capacity": "none",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1591009200,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 159,
        "phase0_start": 1591009200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "153",
        "institutes": "CNB-CSIC (RNA)",
        "country": "Spain",
        "type": "Academic",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1585224000,
        "reference": "https:\/\/fems-microbiology.org\/wp-content\/uploads\/2020\/03\/Enjuanes-Sola-Z\u00fa\u00f1iga-2020.-Novel-Human-Pathogenic-Coronavirus-SARS-CoV-2.pdf",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "LNP-mRNA\u00a0",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 5,200,547 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 160,
        "phase0_start": 1585224000,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585224000,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "154",
        "institutes": "CureVac",
        "country": "Germany\/USA",
        "type": "Commercial",
        "name": "CVnCoV",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "Rabies, Lasa, YF, MERS, Influenza Rota Zika, all Phase 1",
        "capacity": "",
        "alliance": "Bill & Melinda Gates Foundation",
        "phase": "Phase I\/II",
        "start_date": 1583236800,
        "reference": "https:\/\/www.curevac.com\/news\/curevac-ceo-daniel-menichella-ber\u00e4t-mit-us-pr\u00e4sident-donald-trump-und-mitgliedern-der-corona-task-force-entwicklungsm\u00f6glichkeiten-eines-coronavirus-impfstoffes",
        "phase1_country": "Belgium\/Germany",
        "phase1_start": 1592478000,
        "phase1_end": 1630407600,
        "phase1_trial": "NCT04449276",
        "phase2_country": "TBC",
        "phase2_start": 1597662000,
        "phase2_end": 1636459200,
        "phase2_trial": "NCT04515147",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Replicating defective SARS-CoV-2 derived RNAs",
        "annual_revenue": "$14.46M",
        "committed_doses": " 225,000,000 ",
        "total_external_funding": " 97,585,714 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Large external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 161,
        "phase0_start": 1583236800,
        "phase0_end": 1592478000,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1583236800,
            1592478000,
            1597662000,
            0,
            0
        ],
        "end_dates": [
            1592478000,
            1630407600,
            1636459200,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 0
    },
    {
        "number": "155",
        "institutes": "Emergex Vaccines\/George Mason University",
        "country": "UK\/USA",
        "type": "Commercial\/Academic",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "dengue, Influenza, Ebola, Yellow Fever,  Marburg, Chikungunya, ",
        "capacity": "synthetic non-biological vaccine technology - production capacity unknown",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1587553200,
        "reference": "https:\/\/emergexvaccines.com\/emergex-signs-agreement-with-george-mason-university-for-highly-pathogenic-rna-virus-studies\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$885,690\u00a0",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 162,
        "phase0_start": 1587553200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1587553200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "156",
        "institutes": "eTheRNA Immunotherapies",
        "country": "Belgium",
        "type": "Commercial",
        "name": "mRNA TriMix vaccine",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "covid-19",
        "capacity": "cGMP RNA manufacturing - capacity unknown",
        "alliance": "consortium with North American and European partners  - not named",
        "phase": "Pre-clinical",
        "start_date": 1585051200,
        "reference": "https:\/\/www.thepharmaletter.com\/article\/etherna-launches-consortium-and-starts-development-of-cov-2-mrna-vaccine",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$2.72M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 163,
        "phase0_start": 1585051200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585051200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "157",
        "institutes": "FSRI SRC VB VECTOR,\/Rospotrebnadzor, Koltsovo\/(RNA)",
        "country": "Russia",
        "type": "State",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "no information",
        "pipeline": "no information",
        "capacity": "no information",
        "alliance": "no information",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "Intranasal",
        "annual_revenue": "state",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 164,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "158",
        "institutes": "Fudan University\/Shanghai JiaoTong University\/RNACure Biopharma (VLP)",
        "country": "China\/USA",
        "type": "Commercial\/Academic",
        "name": "RNA vaccine (encoding VLP)",
        "platform": "RNA",
        "licenced": "no information",
        "pipeline": "no information",
        "capacity": "no information",
        "alliance": "no information",
        "phase": "Pre-clinical",
        "start_date": 1584705600,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/novel-coronavirus-landscape-ncov.pdf?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "can't find looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 165,
        "phase0_start": 1584705600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584705600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "159",
        "institutes": "Fudan University\/Shanghai JiaoTong University\/RNACure Biopharma\/(RBD)",
        "country": "China\/USA",
        "type": "Commercial\/Academic",
        "name": "RNA vaccine (encoding RBD)",
        "platform": "RNA",
        "licenced": "no information",
        "pipeline": "no information",
        "capacity": "no information",
        "alliance": "no information",
        "phase": "Pre-clinical",
        "start_date": 1584705600,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/novel-coronavirus-landscape-ncov.pdf?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "LNP-encapsulated mRNA cocktail encoding VLP",
        "annual_revenue": "can't find looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 166,
        "phase0_start": 1584705600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584705600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "160",
        "institutes": "GeneOne Life Science\/Houston Methodist",
        "country": "USA",
        "type": "Commercial\/Academic",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "none - DNA plasmids ",
        "pipeline": "DNA based Zika virus, the Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Hepatitis C. Our vaccines against the Severe Fever and Thrombocytopenia syndrome (SFTS) and Varicella Zoster and mRNA based",
        "capacity": "VXGI  Inc. capacity unknown",
        "alliance": "no  information",
        "phase": "Pre-clinical",
        "start_date": 1584446400,
        "reference": "https:\/\/www.houstonmethodist.org\/research\/covid19\/geneone\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "LNP-encapsulated mRNA encoding RBD",
        "annual_revenue": "looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 167,
        "phase0_start": 1584446400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584446400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "161",
        "institutes": "Greenlight Biosciences",
        "country": "USA",
        "type": "Commercial",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "unknown  ",
        "pipeline": "unknown  ",
        "capacity": "unknown  ",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.greenlightbiosciences.com\/covid19\/",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$18.4M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 168,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "162",
        "institutes": "HDT BioCorp",
        "country": "USA",
        "type": "Commercial",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "immune activators",
        "capacity": "unknown",
        "alliance": "PAI Life Sciences, CENTER FOR INNATE IMMUNITY AND IMMUNE DISEASE,  METACENTER FOR PANDEMIC PREPAREDNESS AND GLOBAL HEALTH SECURITY, INBIOS INTERNATIONAL INC",
        "phase": "Pre-clinical",
        "start_date": 1581595200,
        "reference": "https:\/\/www.bizjournals.com\/seattle\/news\/2020\/02\/13\/seattle-biotech-leads-work-on-coronavirus-vaccine.html",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "can't find looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 169,
        "phase0_start": 1581595200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1581595200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "163",
        "institutes": "IDIBAPS-Hospital Clinic (RNA)",
        "country": "Spain",
        "type": "Commercial",
        "name": "mRNA vaccine",
        "platform": "RNA",
        "licenced": "no information",
        "pipeline": "no information",
        "capacity": "no information",
        "alliance": "no information",
        "phase": "Pre-clinical",
        "start_date": 1591009200,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "irrelvant given state funding",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 170,
        "phase0_start": 1591009200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "164",
        "institutes": "Imperial College London",
        "country": "UK",
        "type": "Academic",
        "name": "Self-amplifying RNA vaccine",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "Ebola, Lasa, Mar, Pandemic Influenza, Rabies",
        "capacity": "Inperial Future Vaccine Manufacturing Research Hub - Potential but no infrastructure yet",
        "alliance": "VacEquity Global Health",
        "phase": "Phase I",
        "start_date": 1579089600,
        "reference": "https:\/\/www.imperial.ac.uk\/news\/196313\/in-pictures-imperial-developing-covid-19-vaccine\/",
        "phase1_country": "UK",
        "phase1_start": 1585738800,
        "phase1_end": 1627729200,
        "phase1_trial": "ISRCTN17072692",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " 52,206,518 ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Some external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 171,
        "phase0_start": 1579089600,
        "phase0_end": 1585738800,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1579089600,
            1585738800,
            0,
            0,
            0
        ],
        "end_dates": [
            1585738800,
            1627729200,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 1
    },
    {
        "number": "165",
        "institutes": "Max Planck Institute of\/Colloids and Interfaces (RNA)",
        "country": "Germany",
        "type": "Academic",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1589367600,
        "reference": "https:\/\/www.mpg.de\/14807464\/0511-mpin-116799-corona-vaccination-via-the-skin",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "Academic",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 172,
        "phase0_start": 1589367600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1589367600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "166",
        "institutes": "Moderna\/NIAID",
        "country": "USA",
        "type": "Commercial\/Academic",
        "name": "mRNA-1273",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "2 prophylactic vaccines Ph1",
        "capacity": "Lonza Manufacturing",
        "alliance": "Merck, NIAID",
        "phase": "Phase I\/II\/III",
        "start_date": 1578916800,
        "reference": "https:\/\/www.modernatx.com\/modernas-work-potential-vaccine-against-covid-19",
        "phase1_country": "USA",
        "phase1_start": 1584360000,
        "phase1_end": 1637582400,
        "phase1_trial": "NCT04283461",
        "phase2_country": "USA",
        "phase2_start": 1590750000,
        "phase2_end": 1617188400,
        "phase2_trial": "NCT04405076",
        "phase3_country": "USA",
        "phase3_start": 1595847600,
        "phase3_end": 1666868400,
        "phase3_trial": "NCT04470427",
        "other": "S mRNA plus targeting ligand for Langerhans cells",
        "annual_revenue": "$60.21M",
        "committed_doses": " 104,500,000 ",
        "total_external_funding": " 484,298,520 ",
        "firm_size": "Medium Pharma",
        "funding_category": "Large external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 173,
        "phase0_start": 1578916800,
        "phase0_end": 1584360000,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1578916800,
            1584360000,
            1590750000,
            1595847600,
            0
        ],
        "end_dates": [
            1584360000,
            1637582400,
            1617188400,
            1666868400,
            0
        ],
        "platform_key": 3,
        "funding_key": 0
    },
    {
        "number": "167",
        "institutes": "RNAimmune Inc",
        "country": "USA",
        "type": "Commercial",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "RNA vaccines none identified so far",
        "capacity": "none",
        "alliance": "new spinoff from Sirnaomics to focus on vaccines",
        "phase": "Pre-clinical",
        "start_date": 1588676400,
        "reference": "https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "LNP-encapsulated mRNA",
        "annual_revenue": "can't find looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 174,
        "phase0_start": 1588676400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "168",
        "institutes": "Rochester Clinical Research",
        "country": "USA",
        "type": "Commercial",
        "name": "RNA vaccine",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "this is a CRO",
        "phase": "Phase I",
        "start_date": 1588676400,
        "reference": "https:\/\/www.rcrclinical.com\/clinical-trial\/coronavirus-vaccine-interest-list\/",
        "phase1_country": "USA",
        "phase1_start": 1590750000,
        "phase1_end": 1617188400,
        "phase1_trial": "NCT04405076",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "can't find looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 175,
        "phase0_start": 1588676400,
        "phase0_end": 1590750000,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1588676400,
            1590750000,
            0,
            0,
            0
        ],
        "end_dates": [
            1590750000,
            1617188400,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "169",
        "institutes": "Sanofi Pasteur\/Translate Bio",
        "country": "France\/USA",
        "type": "Commercial",
        "name": "LNP-mRNA vaccine",
        "platform": "RNA",
        "licenced": "DPT, Polio, Hib, Meningococcal, Influenza, Typhoid, Hep A, BCG, etc",
        "pipeline": "HSV, RSV, Pneumo conj, HIV, ",
        "capacity": "a contract manufacturing partner to accommodate at least two 250-gram batches per month.\u00a0 Depending on the final human dose, the mRNA platform of Translate Bio has excellent promise to meet the future demands for a pandemic response.",
        "alliance": "Translate Bio, BARDA",
        "phase": "Pre-clinical",
        "start_date": 1585310400,
        "reference": "https:\/\/investors.translate.bio\/news-releases\/news-release-details\/sanofi-pasteur-and-translate-bio-collaborate-develop-novel-mrna",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$42.127 B",
        "committed_doses": " -   ",
        "total_external_funding": " 502,775,336 ",
        "firm_size": "Large Pharma",
        "funding_category": "Large external funding",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 176,
        "phase0_start": 1585310400,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1585310400,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 0
    },
    {
        "number": "170",
        "institutes": "University of Tokyo\/Daiichi-Sankyo",
        "country": "Japan",
        "type": "Commercial\/Academic",
        "name": "LNP-encapsulated mRNA vaccine",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "none",
        "capacity": "none",
        "alliance": "Daiichi-Sankyo is a large Japanese Pharmaceutical company - no vaccines but some biological oncology  products in development",
        "phase": "Pre-clinical",
        "start_date": 1586602800,
        "reference": "https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/Novel_Coronavirus_Landscape_nCoV_11April2020.PDF?ua=1",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "$280.09M",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 177,
        "phase0_start": 1586602800,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1586602800,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 3
    },
    {
        "number": "171",
        "institutes": "Ziphius Therapeutics\/Ghent University",
        "country": "Belgium",
        "type": "Commercial\/Academic",
        "name": "ZIP-1642",
        "platform": "RNA",
        "licenced": "none",
        "pipeline": "undisclosed other than COVID-19",
        "capacity": "none",
        "alliance": "unknown",
        "phase": "Pre-clinical",
        "start_date": 1584705600,
        "reference": "https:\/\/7dffaa19-682b-4760-bc5a-592e63dfdd3b.filesusr.com\/ugd\/bc1b8f_b6bf5b2e693b4a14aaa51084089eb95c.pdf",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "can't tell looks small",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 178,
        "phase0_start": 1584705600,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1584705600,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "202",
        "institutes": "PLA Academy of Military Sciences",
        "country": "China",
        "type": "State",
        "name": "RNA",
        "platform": "RNA",
        "licenced": "unknown - Military Research Institute",
        "pipeline": "unknown",
        "capacity": "unknown",
        "alliance": "unknown",
        "phase": "Phase I",
        "start_date": 1593082800,
        "reference": "New addition to LSHTM list of candidates July 28, 2020",
        "phase1_country": "China",
        "phase1_start": 1593082800,
        "phase1_end": 1640952000,
        "phase1_trial": "ChiCTR2000034112",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "state",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Bio-tech\/Academic",
        "funding_category": "Bio-tech\/Academic",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 179,
        "phase0_start": 1593082800,
        "phase0_end": 1593082800,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1593082800,
            1593082800,
            0,
            0,
            0
        ],
        "end_dates": [
            1593082800,
            1640952000,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 4
    },
    {
        "number": "223",
        "institutes": "CanSino Biologics\/Precision NanoSystems",
        "country": "China",
        "type": "Commercial\/Academic",
        "name": "mRNA- nanoparticle",
        "platform": "RNA",
        "licenced": "Ebola",
        "pipeline": "meningitis, pneumonia, tuberculosis, COVID-19,\u00a0Ebola virus disease, pertussis, diphtheria, tetanus, shingles",
        "capacity": "pilot plant + commercial manufacturing 70 million to 80 million doses cGMP approved FDA, EU, WHO and China",
        "alliance": "unknown  ",
        "phase": "Pre-clinical",
        "start_date": 1591009200,
        "reference": "https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines",
        "phase1_country": "",
        "phase1_start": 0,
        "phase1_end": 0,
        "phase1_trial": "",
        "phase2_country": "",
        "phase2_start": 0,
        "phase2_end": 0,
        "phase2_trial": "",
        "phase3_country": "",
        "phase3_start": 0,
        "phase3_end": 0,
        "phase3_trial": "",
        "other": "",
        "annual_revenue": "revenue figures hard to find but given bn market cap should be medium",
        "committed_doses": " -   ",
        "total_external_funding": " -   ",
        "firm_size": "Medium Pharma",
        "funding_category": "Medium Pharma",
        "phase0_pos": "",
        "phase1_pos": "",
        "phase2_pos": "",
        "phase3_pos": "",
        "phase4_pos": "",
        "phase0_time": "",
        "phase1_time": "",
        "phase2_time": "",
        "phase3_time": "",
        "phase4_time": "",
        "overlap": "",
        "id": 180,
        "phase0_start": 1591009200,
        "phase0_end": 0,
        "phase4_start": 0,
        "phase4_end": 0,
        "active": 1,
        "update_time": 1598972391,
        "start_dates": [
            1591009200,
            0,
            0,
            0,
            0
        ],
        "end_dates": [
            0,
            0,
            0,
            0,
            0
        ],
        "platform_key": 3,
        "funding_key": 3
    }
]